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Chapter 1: Introduction 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
both globally and nationally. It is an infection with a significant public health impact, 
contributing to the development of a variety of cancers, including cervical squamous cell 
carcinoma, cervical adenocarcinoma, anal cancers, vulvar, vaginal, and penile cancers, 
and oral and pharyngeal cancers. While there is no cure for HPV infection, the HPV 
vaccine, marketed both as Gardasil® by Merck & Co. and Cervarix® by 
GlaxoSmithKline, has been proven to be a highly efficacious tool for prevention. 
However, rates of vaccination among both females and males in the United States remain 
exceedingly low.   
Nationally, there has been very little research conducted on knowledge and 
attitudes regarding HPV and its vaccine. Using a variety of qualitative and quantitative 
methods, this thesis aims to contribute to the research gap through the study of the 
knowledge and attitudes of Hartford, Connecticut adolescents, in collaboration with the 
City of Hartford Department of Health and Human Services. The specific purpose of this 
study is to investigate the barriers, facilitators, and beliefs concerning the HPV vaccine, 
with respect to the intent to be vaccinated among adolescents. This study also pilot tests a 
didactic intervention to address some of the misconceptions surrounding the HPV 
vaccine, allowing adolescents to have the knowledge to gain control of their health and 
make vaccine-related decisions. Ultimately, this study is meant to highlight key areas for 
intervention that will increase knowledge regarding and access to the HPV vaccine, and 
increase vaccination rates among Hartford’s youth. The research was conducted with 
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adolescents utilizing various community resources in the City of Hartford over the course 
of the 2013-2014 and 2014-2015 academic years.   
The pathophysiology and biological mechanisms of HPV  
HPV is a non-enveloped, double-stranded, icosahedral DNA virus. Its virion is an 
8-kb circular genome1, whose relevant proteins are major capsid protein (L1) and minor 
capsid protein (L2), coding for early genes E1-E7 and late structural genes.2,3 
The presence of epidermal or mucosal epithelial cells is a prerequisite for HPV 
infection.4 HPV enters basal cells of stratified squamous epithelium by utilizing viral 
capsid L1. It is thought that this initial step requires microtrauma or mild abrasion of the 
epidermis, such as that that occurs during sexual intercourse.5 The virion then replicates 
episomally, meaning via DNA fragments outside of the chromosome.6 It eventually 
integrates into human DNA within the human cell’s nucleus and uses the host cell’s 
protein-producing organelles to make its infectious proteins. Proteins E1 through E4 
disrupt cytokeratin networks, while subtypes of protein E5 bind the epidermal growth 
factor (EGF) receptor, the platelet-derived growth factor beta (PDGF β) receptor, and 
vacuolar ATPase, interfering with numerous cell functions including MHC class I 
expression and cell-cell communication. E6 and E7 maintain proliferation of the host cell. 
Specifically, E6 binds the p53 tumor-suppressor gene and degrades it via ubiquitination.8 
E7 binds hypophosphorylated Rb and degrades it, resulting in an overexpression of p16, 
used as a biomarker of disease.9-11  
Normally, p53 senses the cell’s damaged DNA, stops the cell from dividing, and 
either activates the cell’s repair systems or triggers “programmed cell death” by 
apoptosis, insuring that a damaged or infected cell does not replicate. 5 When p53 is 
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silenced by E6, the cell replicates even if its DNA is damaged. Rb, meanwhile, normally 
prevents uncontrolled cell proliferation, so when it is silenced by E7, cell division 
progresses unchecked. Thus, cells are essentially “immortalized,” which can lead to the 
formation of a tumor.  
There is evidence that chemotherapy or radiation can reactivate p53 in HPV-
positive tumors, resulting in better outcomes for those with HPV-positive oropharyngeal 
cancer.12 Newer research shows that E6 also interferes with several PSD-95/DLG/ZO-1 
(PDZ) domain-containing proteins, resulting in altered cell polarity, a quality associated 
with tumor progression. This process occurs when E6 binds to and interferes with a key 
protein involved in tight junctions.13 
In the late phase of productive viral infection, the L1 and L2 proteins allow for the 
creation of new virions, which are shed from the cell surface to infect another host. L1 is 
responsible for the icosahedral shape of the HPV virion, can self-assemble into empty 
virus-like particles (VLPs), and is a target for HPV vaccines. L2 enhances the assembly 
of VLPs, facilitates encapsidation of the viral genome into host cells, and after being 
cleaved by the enzyme furin, allows for endosome escape. It then accompanies the viral 
genome to the host cell’s nucleus, where the virus’s genetic material is integrated into 
host DNA.14 
There are more than 150 genotypes of HPV15, classified by sequence of the gene 
encoding the major capsid protein L1.16 HPV types 1-4 are associated with benign skin 
warts. Low-risk types, HPV-6 and HPV-11, are associated with genital warts 
(condylomata), lower-grade squamous intraepithelial lesions of the cervix (LSIL), and 
vulvar intraepithelial neoplasia (VIN 1). High-risk types include HPV-16 and HPV-18, 
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and are associated with cervical intraepithelial neoplasia (CIN) and cervical cancer, as 
well as anal cancer and close to half of all vaginal, vulvar, and penile cancers.17 It appears 
that low-risk types are cleared more easily by the immune system than high-risk 
types18— only the E6 and E7 genes of high-risk types are able to immortalize human 
cells.4,5 As HPV infection requires the presence of epidermal or mucosal epithelial cells, 
it only infects areas where these cells are present, which are the skin, throat, urogenital 
tract, and anus. With respect to cervical cancer specifically, lesions are typically found at 
the squamo-columnar junction, the border between different layers of cervical cell 
types.19 
Epidemiology 
Data show that over half of all sexually active men and 80% of sexually active 
women will become infected at some point in their lives.1,20 HPV is an infection that is 
transmitted by direct contact, which can include genital-to-genital skin contact, as well as 
vaginal, anal, or oral sex. Condoms provide some protection, but regular and consistent 
condom use has shown to only accomplish about 60% protection against infection.21 
HPV can still be transmitted through contact with areas of unprotected genital skin such 
as the vulva or scrotal sacs21, though circumcision has been shown to greatly reduce 
genital HPV prevalence in men.22 Nonsexual routes of transmission are uncommon, but 
can include vertical transmission to an infant at the time of birth.   
Risk factors for HPV infection are related to sexual behavior, such as number of 
concurrent sex partners, lifetime history of sex partners, and partners’ sexual history.20 
One study found that HPV prevalence among women aged 18–25 years was directly 
correlated with the number of lifetime sex partners: prevalence was 14.3% in those with 
5 
 
one lifetime partner, 22.3% for those with two, and 31.5% for those with three or more 
lifetime partners.15 A higher risk of infection is associated with a younger age of sexual 
initiation, an increased frequency of sexual intercourse, and the practice of anal sex.1 A 
prospective study of college women revealed that total incidence of HPV infection was 
40% by 2 years after the onset of sexual activity, with high-risk subtype 16 accounting 
for 10.4% of these infections.20 Age is also an important determinant of risk of HPV 
infection. A review of global data on age-specific prevalence revealed that HPV 
incidence in women is bimodal, with two peak points at <25 and around 45, while in 
men, prevalence and incidence remain consistently high at all ages.23 Other risk factors 
for infection include low socioeconomic status, alcohol and tobacco use, increased 
number of pregnancies, lack of circumcision in male partners, and oral contraceptive 
use.1 
In the United States, the CDC estimates that 79 million individuals are currently 
infected, and 14 million new infections occur each year. Approximately half of these new 
infections occur among those aged 15–24 years.15 Based on data from numerous studies, 
estimates of the prevalence of infection in asymptomatic women among the general 
population in the U.S. range between 2% and 44%, varying based on study samples and 
data collection methods.1 The 2011 National Health and Nutrition Examination Survey 
(NHANES), using polymerase chain reactions (PCR) on self-collected cervicovaginal 
samples from over 4,000 US women between the ages of 14 and 49, placed the overall 
prevalence of HPV infection at 42.5%.22 Prevalence differed by age group, with the 
highest level of infection among females aged 20-24 (53.8%).22 In this age group, 
prevalence of HPV types 6, 11, 16, or 18 was 18.5%.15 Lower levels of infection were 
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seen among those between the ages of 14 and 19 (32.9%).22 As had been seen in previous 
studies, infection was also found to be more prevalent among those of Hispanic or 
African American ethnicity. Prevalence was estimated at 59.2% among non-Hispanic 
Blacks and 44.2% among Mexican Americans, versus 39.2% among non-Hispanic 
Whites.22 
HPV infection is also common in men, and as a result is inextricably linked to 
infection in women. Clinic-based studies among heterosexual men have shown that 
prevalence is often upwards of 20%, though this number is highly determined by the site 
and method of specimen collection.20 In contrast to women, HPV infection is present on 
keratinized surfaces in men, often resulting in poor yield when sampling.22 A large U.S.-
based study examining HPV infection in men revealed a prevalence of 61%, greater than 
that found in women by the NHANES, with the high-risk subtypes of 6, 11, 16, and 18 
found in 23% of the study population .22 Incidence of oral HPV infection is also higher in 
men than women, and NHANES data has demonstrated that men have an incidence rate 
of 10%, versus 4% in women. Unlike in women, there has been no correlation noted with 
age.22 An international study done on men between the ages of 18-70 seeking information 
about sexually transmitted disease testing from clinics in the U.S., Mexico, and Brazil, 
revealed a genital HPV prevalence range of 52-69% by country, again with no age 
correlation.15 
Despite its high prevalence, most HPV infections are cleared by the immune 
system. And once cleared, very few cases reappear, and even fewer lead to clinically 
relevant disease: 70% of all new HPV infections resolve within one year, and 90% within 
two years with no medical treatment.1 A study done of U.S. female college students 
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revealed that the median duration of new HPV infections was only 8 months.1 Numerous 
other studies have shown that the 1 year clearance rate of infection ranges from 40-70%, 
while the 2 year clearance rate ranges from 70-100%.22 Therefore, only a minority of 
HPV cases progress to clinical disease. In these cases, over a course of approximately 12-
15 years, persistent high-risk HPV infection leads to progression through several stages: 
low-grade (LSIL) and high-grade intraepithelial lesions (HSIL), seen cytologically, and 
cervical intraepithelial neoplasia (CIN) grade I-III, seen histologically.1 In cross-sectional 
studies, an estimated 3-5% of women eventually develop cervical cancer without any 
clinical intervention.22 Evidence suggests that those who progress in this way are not able 
to mount a successful cell-mediated immune response against the virus, specifically to 
major capsid protein L1.16 Since L1 determines the viral genotype, previous exposure and 
clearance of HPV infection may confer long-term immunity, certainly to the same 
genotype and perhaps across sub-types as well, though this is not certain due to the 
localized nature of infection. 24, 25 
HPV infection alone, therefore, is not sufficient to trigger progression from 
infection to tumor. Numerous factors have shown to be positively associated with 
persistent infection and the transition from HPV infection to invasive disease. Initial 
infection with a high-risk HPV subtype increases the risk of both persistence and 
progression. The longest course of persistent infection has been seen with HPV subtypes 
16, 31, 54, and 53.22 The E6 and E7 genes play crucial roles in this process. HPV-induced 
carcinogenesis is a multi-step process, so often regular screening can prevent the 
transition to cancer. Therefore, factors associated with infrequent health maintenance 
visits, such as low socioeconomic status, increase the risk of developing HPV-associated 
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cancer. Those of African American or Hispanic ethnicity are also more likely to develop 
malignancy. Since the infection is normally cleared by the immune system, factors that 
cause failure of this control also increase risk. These include older age, tobacco smoking, 
poor nutrition, immunodeficiency, and concurrent infections.1 One trial showed no 
clearance of high-risk HPV infections in women over the age of 70.22 Clearance of 
infection also seems to occur faster in men, with an average clearance time of about 6 
months. One study showed that almost 75% of HPV infections in men were cleared 
within 1 year.22 
Overall, HPV is responsible for approximately 5.2% of all cancers.1 It is a 
necessary, but not sufficient, cause of cervical squamous cell carcinoma (SCC) and 
cervical adenocarcinoma. A study done in 1999 demonstrated that HPV DNA could be 
found in 99.7% of cervical cancer specimens.26 In 2008, the American Cancer Society 
estimated that 11,070 new cases of cervical cancer were diagnosed in the U.S., resulting 
in 3,870 deaths. HPV subtypes 16 and 18 caused approximately 70% of these cases.20 
Additionally, HPV is responsible for approximately 90% of anal cancers, 40% of vulvar, 
vaginal, and penile cancers, and 12% of oral and pharyngeal cancers.20 In the United 
States, 91% of anal cancers have been found to be positive for HPV, 77% of which have 
been HPV 16.15 Of vulvar, vaginal, or penile cancers, the prevalence of HPV 16 and 18 is 
47.9%.27  
According to the CDC, approximately 3,500 cases of HPV-associated vulvar 
cancer and 730 cases of HPV-associated vaginal cancer occur each year.21,28 With regards 
to oropharyngeal cancer, rates have steadily increased for men since the 1970s and for 
females from 2000-2009 in the United States.15 Although the use of tobacco and alcohol 
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are strong risk factors for oropharyngeal cancers, a recent U.S. study reported that 
approximately 72% were positive for HPV, 61% of which had HPV 16. Prevalence of 
HPV 16 and 18 in these cancers was higher in males than females, and lower in non-
Hispanic blacks than in other racial/ethnic groups.15 
The HPV vaccine 
In June 2006, Gardasil®, developed by Merck & Co., became the first vaccine 
approved by the U.S. Food and Drug Administration (FDA) for HPV prevention.29 It was 
licensed for use in girls and women ages 9 to 26 years, and provides protection against 
HPV types 16, 18, 6, and 11. Cervarix®, developed by GlaxoSmithKline, was not 
approved by the FDA until three years later, in October 2009, though it had been in use in 
Europe, Australia, and the Philippines prior to that time.29 It was approved for use in girls 
and women ages 10 to 25 years, and provides protection against HPV types 16 and 18.15   
In October 2009, the same month that the bivalent Cervarix was approved for use 
in females, the quadrivalent Gardasil was approved by the FDA for use in boys and men 
between the ages of 9 and 26 years for the prevention of genital warts. The Advisory 
Committee on Immunization Practices (ACIP) added the vaccine to its recommended 
routine vaccination schedule in October 2011 for males aged 11-12 years, with catch-up 
vaccination up to the age of 21.30 
Pathophysiology 
Like any vaccine, both Gardasil and Cervarix work by generating immunologic 
memory. By exposing individuals to virus subcomponents through vaccination, 
antibodies and cell-mediated immunity develop that protect from natural infection. 
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Although several of these mechanisms are clearly delineated with in vitro and theoretical 
models, it remains unclear exactly how these vaccines specifically prevent natural 
infection from HPV.16 However, several different mechanisms have been explored, and 
each probably plays a role in the protection the HPV vaccine provides.  
 Both Gardasil and Cervarix are composed of L1 coat proteins, which is the viral 
component specific to different HPV genotypes.16 These proteins spontaneously self-
assemble into empty viral protein shells, also called virus-like particles (VLPs).29 VLPs 
are non-infectious, as they contain no viral DNA or infectious viral components.31 As 
with any protein-based vaccine, adjuvants are used to increase immunogenicity. Similar 
to other prophylactic pediatric vaccines, such as Pedvax Hib for Haemophilus influenzae 
and Recombivax for hepatitis B, Gardasil uses an aluminum salt adjuvant, aluminum 
hydroxyphosphate sulfate, which stimulates a Type 2 humoral response in human T 
cells.29 Cervarix uses aluminum hydroxides as well as a bacterial lipid called ASO432, 
which stimulates both Type 1 cell-mediated and Type 2 immune responses.29 Gardasil is 
quadrivalent, meaning it protects against four strains of HPV: 6, 11, 16, and 18. Strains 6 
and 11 cause for 90% of genital warts and strains 16 and 18 cause most cases of cervical 
cancer.  Cervarix is bivalent and only contains L1 proteins of HPV types 16 and 18 for 
protection from these cervical cancer-causing strains.16  
 After the vaccine is injected, VLPs are detected as a foreign protein by 
phagocytes that are programmed to attack non-self proteins. Certain phagocytes, 
specifically called antigen-presenting cells (APCs), break down the proteins, then migrate 
to the draining lymph nodes. In the draining lymph nodes, the APCs can activate specific 
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B-cells that have the potential to make antibodies against the L1 protein.16 After the first 
vaccine, antibodies against the HPV L1 proteins are created.  
 Since HPV infection occurs in the epithelium of the cervix (or other epithelial 
surfaces in cases of anogenital infection) with low levels of inflammation, repeat 
vaccinations are necessary to increase antibody levels and to select for more specific 
antibodies. The HPV vaccine is given in 3 doses at 0, 1 or 2, and 6 months.33 After the 
second vaccine dose, the process of affinity maturation selects for activated B-cells that 
produce more specific antibodies against the L1 protein.34 Very specific antibodies to the 
specific strains in each vaccine develop in high titers after the third dose to protect from 
infection.16  
 Months after the third and final dose is given, long-living plasma cells in the bone 
marrow create persistent low levels of antibodies against HPV. Additionally, memory B 
cells circulate that can recognize HPV antigens and create high levels of antibody upon 
re-exposure. Mathematical models have shown that immunity from infection can 
theoretically last decades after vaccination based on antibody levels after vaccination.35 
Using a conventional power law model, it was estimated that detectable antibodies would 
be found for a median duration of 32 years following three doses of HPV-16 vaccine in 
women ages 16-23 years; a modified power law model predicted life-long persistence of 
antibodies above the level of detection (>5.9 mMU/mL).23 
 It remains unclear how circulating antibodies can prevent in vivo infection in the 
epithelium, since the HPV virus occurs in a low-inflammatory state and rarely causes 
viremia.16 Because of the localized infection, natural infection with an HPV strain is not 
thought to lead to natural immunity.16 However, through the process of repeated 
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vaccination, high enough levels of circulating antibodies in the bloodstream may prevent 
initial infection by preventing the HPV virus from attaching to the epithelial basement 
membrane.36 It appears that up to 40% of vaccinated individuals have antibody levels that 
fall off to background levels, but clinical trials have shown that immunity persist despite 
low antibody levels.36 Presumably, low levels of very specific antibodies after three 
vaccinations can prevent infection and memory B cells may be easily activated upon 
natural infection.16 Regardless of the exact mechanism of the HPV vaccine, both clinical 
trials and population based studies have shown marked decreases in strain-specific HPV 
infection after vaccination.  
Efficacy and Safety 
The HPV vaccine has now been available to the public for approximately 8 years. 
In that time, vaccination programs have been broadly implemented, initially targeting 
only adolescent girls and then including boys by 2009. Both efficacy and safety of the 
vaccine have been extensively researched. The risk of HPV exposure theoretically exists 
throughout one’s sexual life, so overall effectiveness is highly dependent on the duration 
of protection of the vaccine. As of December 2014, the bivalent Cervarix had been 
followed for 9.4 years, while the quadrivalent Gardasil had been followed for 8 years, 
without breakthroughs.37 Through a variety of studies, differing in the methods used in 
the assessment of immunogenicity, sample size, and endpoints, including HPV-associated 
disease and persistent infection, efficacy has been widely demonstrated for both Gardasil 
and Cervarix.15 
Phase III trials were initially conducted to demonstrate efficacy in preventing both 
HPV infection and pre-neoplastic lesions secondary to infection.37 Gardasil was 
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evaluated by the FUTURE I8 and FUTURE II9 trials, while Cervarix was evaluated by 
the PATRICIA and the Costa Rica HPV Vaccine trials.37 All four were randomized 
control trials made up of young women aged 15-26 years (mean 20 years); sample sizes 
ranged from 5,500-18,500.37 Pre-enrollment, participants were tested by PCR for HPV 
DNA to determine both prior and current infection status, though the results did not affect 
enrollment.15 The primary endpoint in all four trials, and the basis for licensure in females 
for both vaccines, was the incidence rate of CIN 2/3 or adenocarcinoma in situ (AIS) 
associated with HPV 16 and 18, serving as a surrogate marker for cervical cancer.15 
Incidence rates of vaginal intraepithelial neoplasia (VaIN2/3), vulvar intraepithelial 
neoplasia (VIN2/3), and anal intraepithelial neoplasia (AIN2/3) were used as secondary 
endpoints and surrogate markers for vaginal, vulvar, and anal cancers, respectively.15 
Invasive cancer could not be used as an endpoint as the standard of care is to screen for 
and treat the above-mentioned dysplastic, pre-neoplastic states.15 
High efficacy of the vaccine against all measured end points was demonstrated in 
all four studies. Those participants who received all three doses, had no evidence of 
current or past infection with HPV upon enrollment, and followed the assigned protocol 
of doses at 0, 1 or 2, and 6 months, demonstrated the greatest efficacy when cases were 
counted 1 month after the third dose.15 In the PATRICIA trial, efficacy in this cohort 
against HPV 16- or 18-related CIN 3 was estimated at 100%.37 In comparison, in the 
same trial, the efficacy among all participants regardless of baseline HPV status with 
cases counted one day after the first dose was 45.7%.37 The difference was attributed to 
the fact that some participants had pre-existing HPV infection at the time of enrollment, 
and the vaccines do not prevent progression of disease in those already infected.15 Prior 
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infection with one HPV type, however, did not diminish efficacy against the other HPV 
types covered by the vaccine.20 In the FUTURE I and II trials, efficacy for HPV 16- or 
18-related CIN2/3 or AIS was 97%, while efficacy against any CIN secondary to HPV 6, 
11, 16, or 18 was 95%.20 Greater than 95% efficacy was observed against VIN2/3 or 
VaIN2/3 and genital warts in the infection-naïve cohort, while greater than 75% efficacy 
was observed in all participants.37 The duration of protection following HPV vaccine is 
not known, but for both vaccines, from all four trials, a subset of participants have been 
followed for greater than 60 months with no breakthrough.20 
Throughout the first three phases of clinical research, antibody titers for the two 
vaccines were measured by different immunoassays, as two different adjuvants are used. 
As mentioned previously, Gardasil uses an aluminum salt adjuvant, aluminum 
hydroxyphosphate sulfate29, while Cervarix uses aluminum hydroxides as well as a 
bacterial lipid called ASO4.32 For both vaccines, greater than 99% of recipients develop 
an antibody response to the HPV subtypes covered 1 month after completing the three-
dose series, indicating that the vaccines are highly immunogenic.20 However, there is no 
known minimal titer determined to be protective or a known serologic component that 
can be measured to test for immunity. It is also difficult to compare the immunogenicity 
of the two vaccines, given the difference in the assays used to measure antibody titers.15 
One study that compared the two vaccines directly by using the same serologic assay 
found that Cervarix provided 2.3-4.8 times higher anti-HPV-16 neutralizing-antibody 
levels and 6.8-9.1 times higher anti-HPV-18 neutralizing-antibody levels than Gardasil 
one month after the 3-dose series completion. Longer-term effectiveness, however, was 
not addressed in this study.38  
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While the initial Phase III trials were only conducted in women, the quadrivalent 
Gardasil has been shown to be efficacious against HPV-related disease in men as well. A 
large-scale randomized controlled study done in 2009 among 4065 healthy males 
between 16 and 26 years of age, 602 of whom were self-reported to have sex with other 
men (MSM), recruited from 18 different countries, demonstrated high efficacy of 
Gardasil against HPV-related external genital lesions.23 Among all participants, efficacy 
against any external genital lesion related to HPV 6, 11, 16, or 18 was found to be 90.4%, 
while efficacy against genital warts and penile intraepithelial neoplasia was 89.4% and 
100%, respectively.39 When broken down by self-reported sexual orientation, the vaccine 
had an efficacy of 92.7% against genital warts among heterosexuals, and 79% among 
MSM; for persistent infection, the vaccine had an efficacy of 50.4% for heterosexuals 
and 43.6% for MSM.23 Against AIN in MSM, efficacy was 77.5%.23 This study 
demonstrated the direct benefits men can receive from the vaccine, but other studies have 
also demonstrated that the vaccine also has an indirect effect on males with only female 
vaccination. In 2007, a study was done in Australia in which females aged 12 to 26 were 
vaccinated with Gardasil with a coverage rate between 65% and 75%. Women and 
heterosexual men under the age of 28 demonstrated a large decrease in incidence rate of 
genital warts from 2004-2007 to 2008, with a prevalence ratio of 0.83 compared to 0.52, 
respectively. This decrease was not seen in MSM or women older than 28, suggesting a 
herd immunity effect.39 
Post-marketing studies have demonstrated the long-term clinical significance of 
HPV vaccination in specific communities. One ecological study conducted in Victoria, 
Australia, compared the incidence rate of CIN 2+ lesions in girls less than 18 years of age 
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both before and after the initiation of a vaccination program with Gardasil in 12-to-13 
year olds. With a vaccination coverage rate of 71-79%, incidence rate has progressively 
decreased by 0.38%.23 Similar studies have been conducted in New Zealand and 
California; coverage rates were under 50% in both regions, but there was a reduction of 
60% and 30% in genital warts, respectively.23 
In addition to being effective, both HPV vaccines have been proven to be well-
tolerated and safe. The vaccines do not contain mercury, thimerosal, live viruses, or dead 
viruses, but only virus-like particles, which cannot reproduce in humans.32 Similar to 
other protein subunit-based vaccines, like tetanus and hepatitis B, the most common 
reported adverse reaction during the Phase III trials was pain at the site of injection, 
which was reported by 91% of those receiving Cervarix, 85% of those receiving Gardasil, 
and 75-78% of those receiving a placebo. Fever was next most common, and was 
reported by 15% of those receiving Gardasil, 12% of those receiving Cervarix, and 11-
12% of those receiving a placebo.29 Rates of serious adverse events, such as autoimmune 
disorders and death, did not differ between those receiving the vaccine and those 
receiving a placebo.15 
Gardasil has been on the market since June 2006, and from then through March 
2014, approximately 67 million doses of the vaccine were distributed in the United 
States. In that same time period, the CDC’s Vaccine Adverse Event Reporting System 
(VAERS) received a total of 25,063 adverse event reports secondary to the vaccine.  
92.4% of those reports were classified as non-serious, which included generalized 
symptoms such as headache, fever, syncope, dizziness, and pallor, as well as localized 
pain. The rate of serious events, classified as those resulting in hospitalization, permanent 
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disability, life-threatening illnesses, or death, peaked in 2009 at 12.8%, but was down to 
7.4% by 2013. Additionally, no statistically significant increased risk has been observed 
for Guillain-Barré syndrome, motor neuron disease, stroke, venous thromboembolism, 
appendicitis, seizures, syncope, allergic reactions, or anaphylaxis.15 In 2008, the media 
targeted Gardasil after reports between June 2006 and December 2008 revealed increased 
numbers of syncopal episodes and venous thromboembolic events (VTEs) following 
vaccination compared to background rates. However, of the 31 women that had 
confirmed cases of VTEs, 28 had underlying risk factors, such as obesity, oral 
contraceptive use, and hypercoagulability disorders.40 The vaccine’s overall safety profile 
is comparable to that of other childhood vaccinations.29 There is less data regarding the 
safety and tolerability of Cervarix, as it was licensed more recently in October 2009, and 
from that time through March 2014, only an estimated 719,000 doses were distributed.15 
In this time period, 113 reports were submitted to VAERS, with 93.8% classified as non-
serious.15 As with Gardasil, these included generalized symptoms such as dizziness and 
headache, as well as localized pain.   
The only absolute contraindication to receiving the HPV vaccine is a severe 
allergic reaction either to a vaccine component or following a prior dose. Deferral of 
vaccination is recommended for those with a moderate or severe acute illness until 
symptom improvement. Both Gardasil and Cervarix are classified as Pregnancy Category 
B meaning they are not recommended for use during pregnancy due to limited data in 
pregnant women, though no risk has been found in animal studies.20 
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Initial Rollout and Controversies 
The Food and Drug Administration licensed Merck & Co., Inc.’s Gardasil for use 
in females aged 9 to 26 years on June 8, 2006. Prior to its approval, it was touted as a 
product with both significant public health and immense blockbuster potential. Merck 
launched a widespread ad campaign, “Tell Someone,” which educated viewers about the 
prevalence of HPV and its link to cervical cancer and resulted in Gardasil being dubbed 
the “Cervical Cancer Vaccine”.41 Later that month, the ACIP issued their 
recommendations for routine HPV vaccination.42 Because the vaccine has the greatest 
benefit when given before sexual debut, the committee recommended three doses of the 
vaccine for 11 and 12 year old females, and vaccination for females between 13 and 26 
years of age who had not been vaccinated previously or who had not completed the 3-
dose series.42 The committee did not take a position on whether vaccination should be 
mandatory by law as such policy decisions are left up to the individual states.43 
These recommendations were met with polarizing debates, fueled by substantial 
media coverage, which overshadowed the vaccine’s public health potential. Some of the 
opposition to Gardasil stemmed from the history of resistance to vaccination and 
specifically, the growing trend of parental refusal of childhood vaccines. One of the 
recent consequences of growing vaccination avoidance was the early 2015 measles 
outbreak in the United States, originating in Disneyland, California, and then spreading to 
multiple other states. The most discussed and feared complication of vaccination has 
been the development of neurological complications, and specifically, autism spectrum 
disorders. This fear originated in 1998, when doctors from London’s Royal Free 
Hospital, led by Andrew Wakefield, released a study published in the Lancet that 
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suggested a link between the MMR vaccination and inflammatory bowel disease, leading 
to autism. Two follow-up studies, commissioned by the British Department of Health in 
1999, could not confirm this link.  However, panic among parents increased 
exponentially.44 
In the following years, multiple advocacy groups, such as SafeMinds, and public 
figures, such as Jenny McCarthy, continued to propagate the idea of a linkage between 
childhood vaccinations and autism.44 A report by the Institute of Medicine (IOM), 
“Immunization Safety Review: Vaccines and Autism,” released in 2004, concluded that 
"the evidence favors rejection of a causal relationship between thimerosal–containing 
vaccines and autism,” also rejecting any link between MMR and inflammatory bowel 
disease. The CDC supported the IOM conclusion.45 Ten of the 13 authors that wrote the 
1998 study published in the Lancet retracted their work in 2004, and Andrew Wakefield, 
the lead author, was stripped of his medical license in 2010.44 Furthermore, a study 
published in 2013 in The Journal of Pediatrics analyzed data from a case-control study 
conducted in three managed care organizations(MCOs) consisting of close to 1000 
children, and studying the possible connection between exposure to total antibody-
stimulating proteins and polysaccharides from vaccines and risk of autism. Exposure to 
these antigens in the first 2 years of life was not found to be linked to risk of developing 
an ASD.46 The American Academy of Pediatrics publishes a yearly document 
summarizing all studies and publications on vaccine safety to date; the 2013 report 
continues to show no link between autism and the MMR vaccine, thimerosal, multiple 
vaccines given at once, fevers, or seizures.47 
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Gardasil received increased scrutiny because it was approved based on the results 
of four clinical trials that only averaged three years in length, leaving questions about the 
duration of its protection and potential long-term adverse effects. Additionally, Merck, in 
its urgency to outcompete the yet-to-be-approved Cervarix by GlaxoSmithKline, 
participated in aggressive lobbying to convince state legislatures to make the vaccine 
mandatory for adolescent girls. Texas was the first state to mandate the vaccine in 
February 2007, when an executive order was issued by Governor Rick Perry requiring 
vaccination for all girls to enter middle school. The media extensively covered the fact 
that Merck partially financed Perry’s reelection campaign and that members of Perry’s 
staff had ties to Merck lobbyists. The order was eventually overturned by a landslide 
decision of 181-3 by the state legislature.48 Additional reports emerged that Merck was 
funding lobbyists in more than 20 other states to work towards mandatory vaccination, 
which led the company to eventually stop funding lobbying on the issue.48 In May 2007, 
Arizona’s legislature approved a bill prohibiting the state's health department from 
requiring the vaccine, while nationally, a Republican congressman introduced the 
Parental Right to Decide Protection Act, meant to prohibit the use of federal money to 
establish mandatory HPV vaccination programs.49 By the end of May 2007, the only state 
to make Gardasil a legal requirement was Virginia.50   
Other controversies arose regarding the idea of mandatory vaccination, 
particularly because HPV is a sexually transmitted infection.51 Opponents of a vaccine 
mandate argued that HPV is not spread by casual contact or airborne droplets, and 
therefore, there is no immediate risk of infection in schools.48 Rather than creating herd 
immunity, then, a mandate would only protect the individual vaccinated, which has been 
21 
 
argued is an invasion of individual and parental rights.52 Similar arguments in the past 
had been raised regarding vaccination against hepatitis B, which is spread by sexual 
contact and intravenous drug use. In both cases, targeting specific at-risk groups to 
receive the vaccine would be less effective than universal vaccination.43 Some raised 
moral objections to making a vaccine for a sexually transmitted disease mandatory.50 
Organizations such as Focus on the Family and the Christian Medical Association took a 
stand against mandatory vaccine, preferring that the decision to vaccinate be a parental 
one, though ultimately came to support availability of the vaccine itself.48 Other parents 
argued that due to religious values or other personal beliefs, their children would remain 
abstinent, and therefore uninfected, until marriage, making a vaccine mandate 
unnecessary.52 However, according to the CDC, 13% of girls in the United States are 
sexually experienced by the age of 15, 43% by the age of 17, and 70% by the age of 19. 
Additionally, the rate at which adolescents drop out of school starts increasing at the age 
of 13. Therefore, to reach the majority of vulnerable women while they are still in school, 
a mandatory vaccine program would ideally begin at age 12.52 The University of 
Michigan C.S. Mott Children’s Hospital National Poll on Children’s Health, conducted 
online in March 2007, found that only 44% of parents supported the idea of a HPV 
vaccine mandate48, compared to 68% for the tetanus-diphtheria-pertussis (Tdap) 
vaccine.49 Allowing religious or philosophical exemptions to the vaccine would have 
alleviated some of the concern over a vaccine mandate, though studies with other 
vaccines have found greatly reduced vaccination rates when this is an option.43 
The most vocal opponents maintained that the use of Gardasil would promote 
promiscuity among teenagers. The argument was that there would be “disinhibition,” 
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defined by the CDC as "an increase in unsafe behaviors in response to perceptions of 
safety caused by introduction of a preventive or therapeutic intervention." The same 
argument has been made regarding needle exchange centers and rates of drug use, as well 
as condom distribution and rates of unwanted pregnancies and sexually transmitted 
diseases.41 This idea was perpetuated by the media, with such headlines as "Cervical 
Cancer Vaccine Gets Injected with a Social Issue: Some Fear a Shot for Teens Could 
Encourage Sex" in the Washington Post.41 However, this concern has been proven to not 
be the case. Numerous studies have shown that the HPV vaccine does not promote 
promiscuity.51 Most recently, a study published in the Canadian Medical Association 
Journal in December 2014 demonstrated similar rates of pregnancy and sexually 
transmitted infections, used as surrogate markers of increased unsafe sexual activity, in 
two cohorts of vaccinated (n= 128,712) and unvaccinated (n= 131,881) girls in Ontario.53 
Finally, concerns were raised by both providers and patients regarding barriers to 
access. Some argued that additional populations that could benefit were not included in 
the ACIP’s recommendations, which at the time, only included females. By only 
recommending routine vaccination for girls aged 11-12 prior to first sexual contact, older 
and sexually active people, as well as males, were being deprived of the potential benefits 
of the vaccine.54 On the other hand, some argued that it was a matter of gender inequity 
that only girls were compelled to submit to the new vaccine.49 
When GlaxoSmithKline’s bivalent Cervarix vaccine was licensed in the United 
States in 2009, the ACIP revised their recommendation to include both vaccines.42 Prior 
to receiving approval in the United States, Cervarix had been licensed in over 100 
countries.55 Cervarix proved to be as safe and effective as Gardasil against HPV 16 and 
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18, but regulatory delays kept it out of the U.S. for several years.55 While both HPV 
vaccines had been recommended for girls since 2009, it was not until 2011 that the ACIP 
recommended routine use of Gardasil for males as well42, which had been licensed for 
male use in 2009.56 The ACIP added Gardasil to its recommended routine vaccination 
schedule for males aged 11-12 years, with vaccination up to the age of 21 for those who 
had not been vaccinated previously or who had not completed the 3-dose series.30  
Debate following Gardasil’s approval and recommendation for male use was 
muted compared to that which followed recommendations for females in 2006. This 
lesser reaction is perhaps due to the double standard that exists in which early sexual 
activity in boys is more accepted than it is in girls. Controversy primarily centered on the 
fact that some HPV-related cancers in men, such as anal or oral cancer, result from male 
to male sex, and that there is a higher prevalence of HPV infection among gay men.49 
Additionally, cost was an issue. The price of Gardasil is steep, totaling 
approximately $360 for three doses plus associated office visits.48 It was estimated that 
vaccinating all 11 and 12-year-old boys in the United States would cost approximately 
$140 million annually, while catch-up vaccination among males ages 13 to 21 years 
would cost hundreds of millions more. Generally, the U.S. government pays for about 
half of all vaccinations, which was a source of contention.57 A study authored by 
Bogaards et al. (2011) used mathematical models to determine cost effectiveness of the 
vaccine among both genders, and concluded that increasing vaccine uptake among 
preadolescent girls would be more effective than starting routine vaccination for 
preadolescent boys in decreasing HPV infection rates.58 The authors state that, “As a rule, 
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directing prophylactic immunization at the sex with the highest pre-vaccine prevalence 
results in the largest reduction of the population prevalence”.58 The ACIP addressed the 
concerns about the cost-effectiveness of the vaccine in their 2011 routine 
recommendation for boys, noting that "a range of assumptions," including the vaccination 
rates for girls, can affect how much each prevented case of infection cost.57 Nonetheless, 
the ACIP concluded HPV vaccination would be worthwhile for boys and men up to 21, 
as vaccinating boys also benefits female partners. Models demonstrated that vaccinating 
only men having sex with men (MSM) would have been more cost effective than 
vaccinating all boys, due to the difference in prevalence rates, but studies among 
providers revealed general uneasiness in making those determinations at the 
recommended vaccination age of 11-12 years old.57 
Current Recommendations 
Both Cervarix and Gardasil are currently available on the market for use against 
HPV infection. Gardasil is licensed by the FDA for the prevention of vulvar, anal, 
cervical and vaginal cancers, as well as genital warts. It is approved for use in females 
ages 9 through 26 and for males between the same ages.59 Cervarix is licensed for the 
prevention of cervical cancer, cervical intraepithelial neoplasia, and other precancerous 
lesions caused by oncogenic HPV types 16 and 18 in females aged 9 to 25 years.60 Since 
clinical trials of both Gardasil and Cervarix have only explored their effectiveness against 
cervical cancer precursors and genital warts, they currently do not have FDA approval for 
protection against other types of HPV-associated cancers, including other anogenital 
cancers and oropharyngeal cancers.15 
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Currently, the ACIP recommends that girls and boys aged 11-12 years receive the 
HPV vaccine as part of their routine care, although vaccinations can begin as young as 9 
years of age.15 Females can receive either Gardasil or Cervarix, while only Gardasil is 
recommended for males. Both vaccines are given as a three dose series of intramuscular 
injections over a period of six months. Current recommendations maintain that the 
second dose should be administered one to two months after the first dose, and the third 
dose six months after the first dose.15 However, there is no maximum interval between 
doses, and if the schedule is interrupted, the series does not need to be restarted.20 The 
HPV vaccine may be administered at the same time as other vaccines recommended in 
the same age range, such as such as Tdap and quadrivalent meningococcal conjugate 
(MCV4) vaccines, as it is likely to improve schedule adherence.15 The HPV vaccine is 
considered to be most effective in 11 or 12 year olds because it is less likely that these 
individuals have had sexual intercourse, based on the average age of sexual debut in the 
United States.15 Additionally, data on HPV epidemiology, cost-effectiveness evaluations, 
and pre-marketing clinical trials, which demonstrated the highest post-vaccination 
antibody titers at age 11 or 12 compared to older age groups, is the basis for the routine 
vaccination recommendation at age 11 or 12 years.15 
A "catch up" vaccination is recommended for females and males aged 13 to 26 
years who have not either been previously vaccinated or completed the series.15 Full 
benefit would be received by those not yet sexually active. As a non-therapeutic 
treatment, neither vaccine can treat nor cure existing conditions caused by HPV, such as 
persistent infection, pre-neoplastic lesions, or genital warts. However, the vaccines would 
protect against genotypes not already acquired.15 Current evidence demonstrates that only 
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a small percentage of sexually active individuals in these recommended catch-up age 
groups have been infected with both HPV 16 and 18 or all four HPV types covered by the 
vaccines.15 There is currently no approval from the FDA for use in individuals greater 
than 26 years of age; however, if an individual initiates the series, but does not complete 
it prior to turning 26, the remaining doses can still be administered afterwards.20 Other 
recommendations from the ACIP include giving the three dose series to (1) females under 
the age of 27 with abnormal Pap smears (2) females under the age of 27 with a positive 
HPV DNA test (3) females or males under the age of 27 with a history of genital warts 
(4) females or males under the age of 27 with immunosuppression, whether secondary to 
disease or medication and (5) females under the age of 27 who are breastfeeding.15 
No studies have been done on the interchangeability of Gardasil and Cervarix, so 
currently, the ACIP recommends that the same HPV vaccine be used for the entire three 
dose series.15 One vaccine has not been endorsed over the other55, but rather, the official 
recommendation allows for the administration of either vaccine.42 Currently, the only 
known difference between the two vaccines is the protection against genital warts offered 
by Gardasil.55 There is no known difference in regard to immunogenicity, duration of 
immunity, or cross-protection, as well as no significant price difference. The ACIP has 
emphasized that the primary goal of vaccination is cervical cancer prevention, and the 
best way to reach this goal is to have both vaccines available to the public. If one vaccine 
was preferentially recommended over the other, the lesser-preferred vaccine might drop 
off the market, which could lead to frequent shortages in the supply of the recommended 
vaccine.55 The ACIP’s current recommendation of either vaccine has allowed for 
protection against supply disruptions, and has provided insurance if safety issues emerge 
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for one vaccine in the future.55 However, since 2006, whether because of the earlier 
approval date or its unique coverage of the HPV strains that result in genital warts, most 
HPV vaccine administered in the U.S. has been Gardasil.15   
Current National Policies 
The United States, along with Australia, Canada, and the United Kingdom, were 
the first countries to include HPV vaccination in their national immunization programs.56 
Financing for HPV vaccination is not uniform in the U.S., but rather, is a mixture of 
public and private funding. It is estimated that in the U.S., about 56% of routine 
childhood vaccines are publicly funded, while the remainder are financed by the private 
sector.54 Because they are recommended by the ACIP, both vaccines are covered under 
the CDC’s Vaccines for Children (VFC) Programs.61 The VFC provides federally 
purchased vaccines to enrolled private and public healthcare providers for use among 
children who are Medicaid-dependent, underinsured (seen at Federally Qualified Health 
Centers), uninsured, or American Indian or Alaskan Native, through the age of 18.15 
Under the VFC, about 32% of adolescents are eligible for HPV vaccination.56 Those that 
did not qualify for the HPV vaccination series prior to the Patient Protection and 
Affordable Care Act of 2010, had to rely on privately financing, either through out-of-
pocket expenses or private insurance. However, non-grandfathered private insurance 
plans must now cover HPV vaccination at no cost for those that fall into the ACIP’s 
recommended age ranges.62 Children eligible for the State Children’s Health Insurance 
Program (SCHIP) are also covered, as SCHIP programs must reimburse for vaccines 
recommended by the ACIP.63 Additionally, a vaccine assistance program funded by 
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Merck is available to uninsured women between the ages of 19 and 26, and requires care 
be provided by a private physician who already distributes other Merck products.63 
In 2006, after Gardasil was approved by the FDA, the ACIP did not take a 
position on whether vaccination should be mandatory by law as such policy decisions are 
left up to the individual states.43 In turn, some state legislatures granted their Health 
Departments the power to require vaccines.64 To date, at least 25 states and territories 
have enacted legislation on HPV vaccinations: Colorado, District of Columbia, Illinois, 
Indiana, Iowa, Louisiana, Maine, Maryland, Michigan, Minnesota, Missouri, Nevada, 
New Mexico, New York, North Carolina, North Dakota, Oregon, Puerto Rico, Rhode 
Island, South Dakota, Texas, Utah, Virginia, Washington and Wisconsin.64 School entry 
mandates have been effective in increasing uptake for other vaccines, so many of these 
states included a school mandate in their legislation, leading to much controversy.42,64 To 
date, only the District of Columbia and Virginia have mandated vaccination. In this state 
and district, girls must receive all three doses of the HPV vaccine, with compulsory series 
initiation prior to entry into sixth grade, unless religious, moral, or medical exemption is 
claimed.62,64 
Texas was the first state to attempt a vaccine mandate in 2007, when an executive 
order was issued by the governor requiring vaccination for all girls to enter middle 
school, but the order was quickly overturned by the state legislature.48 New York and 
Kentucky currently have pending legislation that would make the vaccine mandatory for 
school entrance with an “opt-out” policy, which are both in various stages of committee 
review.64 As of January 2015, three states (Hawaii, Indiana, and New York) have 
proposed HPV-related legislation for the 2014-2015 session.64 
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More than twenty other states currently have laws in place that recommend HPV 
vaccination, provide funding for the vaccine, and/or support public education about HPV 
and its vaccine.62 A number of states, including New Hampshire and South Dakota, have 
laws that require providers to cover the cost of the HPV vaccine, as well as provide 
federal and state funding to deliver the vaccine for no cost through their health 
departments.63,64 Some states, such as North Carolina and Washington, have added the 
HPV vaccine to their universal vaccine programs.63 In regards to education, several states 
have laws mandating that schools/health departments distribute educational information 
about the vaccine to parents. Indiana further requires that parents of girls entering middle 
school provide a statement of their HPV vaccination decision, which is then 
communicated to the state health department.64 
Uptake and Barriers 
Despite its proven safety and efficacy, current HPV vaccine uptake in the United 
States is inadequate. Using data from the 2007-2013 National Immunization Survey-Teen 
(NIS-Teen), the CDC reported that 57.3% of females aged 13-17 had received at least 
one dose of the HPV vaccine in 2013, an increase from 25.1% in 2007 and 53.8% in 
2012, but that only 37.6% had completed the series.15 Vaccination rates for boys in the 
same age range in 2013 were even lower, with only 34.6% having received at least one 
dose, still an increase from 20.8% in 201215, while 13.9% had completed all three doses, 
which was an increase from 6.8% in 2012. These statistics are extremely low compared 
to administration rates of other vaccines.65 The CDC estimates that if the vaccine had 
been administered to all adolescent girls born in 2000 during routine health care visits 
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when they received their other vaccines, vaccination coverage for at least one dose by age 
13 years in this cohort would have been 91.3%.66 
The national immunization rates above mask significant variation among 
subpopulations. Coverage rates were higher for Hispanics than for Caucasians among 
girls who received any number of doses of the vaccine. The series completion rate was 
markedly lower among African American females, compared to White and Hispanic 
girls. Among boys who received any number of doses of the vaccine, coverage was 
greater among Hispanic and African American males compared to Caucasians. 
Socioeconomic status also affected coverage rates: overall, coverage for 1 or 2 doses of 
the vaccine was higher for girls below the poverty level, compared to those living at or 
above the poverty level, with no difference seen in the series completion rate. Coverage 
for any number of doses of the vaccine was greater for boys below the poverty level. 
Additionally, coverage varied widely between states. The percentage of girls between the 
ages of 13 and 17 who received at least one dose of the vaccine ranged from 39.9% in 
Kansas to 76.6% in Rhode Island. For boys, coverage ranged from 11.0% in Kansas to 
69.3% in Rhode Island.67 
Various studies have identified age, race, education, and socioeconomic factors as 
major factors that affect vaccination rates. Those closer to the minimum age of 9 for 
vaccination have demonstrated lower uptake than older, high school aged adolescents, 
possibly because parents have an inaccurate perception of their children’s sexual 
activity.68 Providers are also often unaware or do not ask about adolescent sexual health, 
including age of sexual debut. This lack of awareness may reduce a physician’s ability to 
recommend vaccination at the appropriate age.69 A recent study done among 124 parents 
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and 37 providers, investigating missed opportunities for HPV vaccination in adolescent 
girls, found that providers who delayed recommending the HPV vaccine to girls 
perceived to be at low risk for early sexual activity reported the lowest vaccine coverage 
rates among their patients. The same study demonstrated that providers did not feel they 
were able to adequately predict age of sexual debut among their patients.70 Vaccine 
coverage for 10-14 year old girls in the United States has been estimated to be as low as 
14%.71 
Ethnicity is also a critical factor in vaccine uptake, as African American and low-
income young women, in particular, are far less likely than Latina, White, or higher-
income young women to receive the HPV vaccine.72 Low-income and minority 
adolescents are equally or more likely to start the HPV vaccination series, but are less 
likely to complete the series. While 50% of African American females initiate the HPV 
vaccine series, compared to 51% of Caucasian females, only 29% complete the series, 
compared to 34% of Caucasian females. Latina females tend to do a bit better, with 63% 
receiving at least one dose, and 36% completing the series.73 Several studies have noted 
that Hispanics are much more likely to take up the HPV vaccine than African Americans, 
but the reasons for this difference are not yet clear .74-79 It is likely that social networks 
and perceived social support play an important role in increasing uptake. Particularly in 
Hispanic or rural communities, researchers have found that if young women and/or 
parents feel that it is socially desirable to receive the HPV vaccine, then they will do so 
with greater frequency.80,81 Lack of information, concern about side-effects, lack of 
health insurance and logistical challenges to series completion have been cited as major 
barriers to vaccine uptake among African American populations.73 African American 
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women have higher rates of HPV infections than do women of other ethnic groups. 
Additionally, the 2011 Youth Risk Behavior report found that 14% of African American 
girls initiate sexual intercourse prior to the age of 13, compared to 7.1% of Latinas and 
3.9% of whites, highlighting the need for early HPV vaccination in this ethnic group.73 
Knowledge, and resulting attitudes, regarding HPV and its vaccine also affect 
vaccination rates. Knowledge levels have generally been found to be poor across both 
genders. A cross-sectional study done in 2007 in women ages 18-75 demonstrated that 
only 40% of women had ever heard of HPV, and of those 40%,  less than half knew it 
caused cervical cancer.82 Another study surveying over 1,500 college students enrolled at 
a large public university in the Northeast United States in 2009 established that 13.6% of 
participants were unclear about the prevalence of HPV infections, 51.5% did not know 
that HPV is transmitted by skin-to-skin contact, and 72% did not know that HPV cannot 
be transmitted via bodily fluids. Participants were also misinformed about the fact that 
most women with HPV infections do not develop cervical cancer.83 A systemic review of 
studies looking at HPV-related beliefs and HPV vaccine acceptability has shown that 
vaccine acceptability is higher when people have a high level of knowledge regarding 
HPV infection, believe the vaccine is effective, and believe they are susceptible to HPV 
infection.84 Parental knowledge and beliefs are also influential in acceptance of the 
vaccine. In the 2013 NIS-Teen, 23.0% and 37.4% of surveyed parents did not intend to 
vaccinate their daughters and sons, respectively, in the following year.66 They were asked 
to identify the main reason why they did not want to vaccinate their child. The top four 
main reasons provided were a lack of knowledge, a belief that the vaccine was not 
needed, the vaccine not being recommended by their health care provider, and concerns 
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about vaccine safety and/or side effects. Lack of knowledge was cited by the parents of 
both girls and boys (15.5% each), as was the belief that the vaccine was not needed (girls: 
14.7%; boys 17.9%).66   
Provider recommendation is one of the strongest facilitators of vaccine uptake and 
conversely, a lack of provider discussion and recommendation leads to lower uptake. A 
national computer-based survey conducted in 2010 revealed that individuals whose 
health-care providers “strongly recommended” vaccination as compared to those whose 
providers “recommended” vaccination were more likely to complete the 3-dose HPV 
series.85 In the 2013 NIS-Teen, 22.8% of parents of boys cited a lack of provider 
recommendation as the main reason for not vaccinating their child, while among parents 
of girls, 13.8% cited this reason.66 
There is a connection between low coverage rates and a lack of insurance .59 
Numerous studies have shown that socioeconomic factors such as proximity to healthcare 
facilities, availability of insurance and cost of vaccine were factors that contributed to 
differential vaccine uptake.79,84,86-89 In the case of HPV, cost is the major barrier, given 
the steep pricing of both Gardasil and Cervarix. According to the CDC’s pediatric/VFC 
Vaccine price list, Merck’s HPV-Quadrivalent Gardasil® has a packaging CDC cost/dose 
of $107.156, and a private sector cost/dose of $141.38. GlaxoSmithKline’s HPV-Bivalent 
Cervarix® has a packaging CDC cost/dose of $100.85, and a private sector cost/dose of 
$128.75.90 However, there are numerous free vaccine programs, including VFC and 
SCHIP, as described previously. 
Due to the only recent recommendation for routine HPV vaccination in boys, 
there has not been as much research on uptake and barriers as there has been in girls. It is 
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known that vaccine uptake in boys is profoundly lower than in girls, as described 
previously. As in girls, racial and socioeconomic disparities have been seen with 
coverage. Caucasian males are less likely to initiate vaccination than Latino and African 
American males, 20.8% compared to 25.9% and 31.7% respectively. Those with a family 
income above the federal poverty line are also less likely to start the vaccination series 
(17.3%) than those below the poverty line (29.9%). Various surveys conducted among 
parents have demonstrated that low-income and minority parents are highly receptive to 
male HPV vaccination, as compared to higher-income and Caucasian parents.73 Series 
completion is poor across the board, with only 4.6% of Caucasian boys, 5.4% of African 
American boys, and 12.9% of Latino boys completing the 3 dose series.73 Results from 
the 2010-2011 NIS-Teen revealed that parents of boys were more likely to initiate 
vaccination if they had received a healthcare provider recommendation or if their child 
was eligible for the VFC program.30 Parental concerns over the perceived potential for 
encouraging or increasing promiscuity have been cited in many studies as barriers to 
wider adoption of the HPV vaccine. Further complicating this association, the 
recommendation for boys has been linked to oral and anal sex, suggesting special risks 
for adolescents having male to male sex.   
Studies have demonstrated a high prevalence of STIs and HPV among MSM. A 
1-year prospective cohort study investigating the early sexual behaviors of MSM found a 
HPV prevalence of 69.6% over the course of 1 year, with an incidence rate of 38.5/1000 
person-months. This report also indicated that while many had heard of the infection, 
very few could identify the virus as the cause of anal or oral cancers.  Only 14% 
identified HPV as a serious problem.91 The coverage rate for this population is currently 
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unknown. 
Health education 
Given that prior research has shown that knowledge and attitudes regarding HPV 
and its vaccine greatly impact vaccination rates, this project aimed to educate participants 
through a didactic presentation. Health education is a critical tool in improving the health 
of a population, as it increases individuals’ capacity to access and use health information 
to gain control of their health.  
The World Health Organization defines health education as “consciously 
constructed opportunities for learning involving some form of communication, designed 
to improve health literacy, including improving knowledge, and developing life skills, 
which are conducive to individual and community health”.92 Health literacy, in turn, has 
been defined as “the capacity to obtain, process and understand basic health information 
and services required to make informed decisions that will allow health-enhancing 
actions at the individual, social, and environmental levels”.93 Current evidence shows that 
the educational programs most likely to achieve positive, informed change incorporate a 
complete understanding of both targeted health behaviors and the environmental context 
in which they occur.92 The three basic categories of health education are primary, 
secondary, and tertiary. Primary education seeks to reinforce good health habits which 
may or may not already exist. This ideally leads to preventive health behavior, where an 
individual, who perceives himself to be in a state of good health, takes on an activity with 
the goal of preventing or detecting disease. Secondary education aims to either avoid a 
decline in health or restore good health if such a decline has already occurred. This 
ideally leads to illness behavior where an individual who perceives himself to be ill takes 
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on an activity to either define that illness or determine appropriate treatment. Finally, the 
goals of tertiary education are rehabilitation and adaptation, following some sort of 
deterioration in health. This should lead to sick-role behavior, which is when an 
individual receives treatment.94,95 Therefore, the continuum of health education covers 
preventive care and the promotion of optimal health to the detection of illness and 
treatment. In the case of this study, the goal was primary education, to lead to the 
prevention of HPV through accessing HPV vaccination. 
Current evidence suggests that parental health literacy does not affect health care 
utilization among adolescents, despite the assumption that adults make health care 
decisions for their children.93 One study investigating an adolescent population with 
asthma demonstrated no association between parental health knowledge and child health 
care use. Additionally, studies among first- and second-generation immigrant families 
show that parents often have limited interactions with the American health care system.93 
Therefore, it is hypothesized that adolescent health literacy plays a significant role in 
health care utilization in general and in the uptake of HPV specifically.  
Several intervention planning models, based on health behavioral theories, were 
considered in developing the informational tools utilized in this project, that include:  (1) 
intrapersonal, with a focus on individual capacity; (2) interpersonal, with a focus on 
support groups; or (3) environmental, with a focus on institutional, community, or public 
policy factors.92 The only theories that were considered for this study were those of an 
intrapersonal nature, which attempt to modify individuals’ knowledge, beliefs, attitudes, 
and intentions. There are six theories that fall into this category. The first is the rational 
model, which, through the presentation of unbiased information, seeks to encourage 
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positive and prevent negative health behaviors among individuals to create positive 
behavioral change.92 The disadvantage to this model is that knowledge is usually not 
sufficient to create behavior change. The second theory is the health belief model, which 
reasons that the greater an individual’s perceived severity of and susceptibility to a 
disease, the greater his willingness to take preventive measures.92 Additionally, this 
model argues that an individual is more likely to create positive behavioral change when 
the perceived benefits of that change are greater than the perceived barriers. The third 
theory is the extended parallel process model, which tries to create change with “fear 
tactics,” presenting information that is biased and/or emotionally arousing.92 In this 
model, those individuals with a high perceived susceptibility to and severity of disease, as 
well as high perceived efficacy (i.e. confidence in one’s own ability to prevent harm), 
will be the most likely to create positive change. The fourth theory is the transtheoretical 
model of change, which defines five stages of behavioral change: precontemplation, 
contemplation, preparation, action, and maintenance.92 The fifth theory is the theory of 
planned behavior, which argues that intent to create positive behavior change is necessary 
for both achieving and maintaining that change.92 This model assumes that attitudes of 
both the individual creating the change as well as members of their social group affect 
intent. Finally, the sixth theory is the activated health education model, which consists of 
three phases: the experiential phase, the awareness phase, and the responsibility phase. 
These phases respectively involve an individual assessing his own health, receiving 
information about the target positive behavior change, and then implementing that 
change.92   
38 
 
 Successful education occurs with an understanding of context, so communication 
barriers, including physiological, environmental, psychological, and cultural barriers, as 
well as demographic factors, such as age, sex, educational level, and employment, play a 
major role in determining the best method of dissemination.96 Community-based health 
education, particularly, should rely on social relationships and organizations to reach 
large populations.95 In this study, an effort was made to learn from adolescent 
participants, understanding the cultural and ecological context in which they exist, by 
collecting feedback on the educational intervention utilized in this project. These 
comments will be used to improve the effectiveness of future interventions. 
Specific Aims 
This study uses youth groups and physicians to investigate: (1) the knowledge of 
adolescents concerning HPV and the HPV vaccine, with a particular focus on perceptions 
regarding susceptibility to and severity of contracting HPV; (2) attitudes and beliefs 
regarding HPV and the HPV vaccine; (3) the main barriers and facilitators to vaccination 
in Hartford; (4) the role of education in shaping knowledge base, perceptions, and 
participation in vaccination; and (5) the effects of the opinions of peers, parents, media, 
and physicians on vaccination decisions.  
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Chapter 2: Setting 
This project was conducted in Connecticut’s capital city of Hartford, in 
collaboration with the City of Hartford Department of Health and Human Services. The 
2010 Census placed Hartford’s population at 124,775, 3.5% of Connecticut’s total 
population of 3,574,097. More recently, in 2013, Hartford’s population was estimated at 
125,017, a 0.2% increase since 2010.97 Of Hartford’s total population in 2010, 25.8% 
were under the age of 18, while 51.7% were female. Hartford has a predominantly 
minority population: 29.8% white, 38.7% black or African American, 43.4% Hispanic or 
Latino, 0.6% American Indian or Alaska Native, and 2.8% Asian.97 The large minority 
population is reflected in the demographic composition of Hartford’s public schools; 90% 
of enrolled students in Hartford’s district schools were students of color in 2012.98  
Connecticut is the most economically disparate state, with several of the richest 
and poorest cities in the United States. Hartford falls into the latter category, with an 
average family income of only $42,775. Three out of ten families in Hartford live below 
the federal poverty line, which in 2011, was $22,811 for a family of four.99,100 Moreover, 
there is a high poverty rate among children under the age of 18; according to the 
American Community Survey, the rate in 2012 was 47.9%.99 However, Hartford’s 
metropolitan region, which includes Hartford, Tolland, and Middlesex countries, is the 
13th richest metropolitan area, as defined by the Census, with an average family income 
of $99,597 in 2009. This is an income gap of approximately $56,000 between the city of 
Hartford and its surrounding counties for an average family.100 Statewide, poverty rates 
for African Americans and Hispanics are vastly higher, at 22.9% and 27.3%, 
respectively, in 2011, than those for non-Hispanic whites (6.2%).99  
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With this striking level of poverty, it is important to know a population’s 
insurance status, especially while investigating a health intervention that is as expensive 
as the HPV vaccine. The U.S. Census Bureau, using data from the American Community 
Survey, releases yearly estimates for health insurance coverage in each state. In 2011, 
approximately 8.8% of all individuals in Connecticut were uninsured, though a more 
recent estimate in 2013 placed the uninsured rate at 9.4%.99,101 Children under the age of 
18 had an uninsured rate of 2.9% at the time of the 2011 survey. Rates ranged between 
cities from 10.5% in Waterbury to 23.3% in Bridgeport. Hartford’s rate was mid-range, at 
18.3%, with 6.9% of all children under the age of 18 years underinsured. As with poverty 
rates, statewide, uninsured rates for African Americans and Hispanics were significantly 
higher, at 12.1% and 20.4%, than that for non-Hispanic whites (5.9%).99 These state and 
city uninsured rates seem low compared to the poverty rates discussed previously, likely 
because of recent state and federal health care reforms, which have expanded Medicaid 
eligibility for adults below the federal poverty line without children, allowed children to 
stay on their parents’ insurance up until the age of 26, and expanded eligibility for parents 
and pregnant women in the state’s HUSKY insurance program.99 
Perhaps related to the large economic disparities that exist between Hartford and 
the rest of the state, there is a significant achievement gap between the Hartford Public 
School District and most other school districts in Connecticut. Data released by the 
Connecticut State Department of Education for the 2008-2009 school year revealed that 
only 27.9% of students performed at “goal” level on standardized tests in Hartford, with a 
four-year high school graduation rate of 42%. Only 61% of adults in Hartford have a high 
school diploma.102 More recent data from the 2012-2013 school year revealed a stable 
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four-year high school graduate rate of 42.5%, with a dropout rate of 23.6%.103 The 2008-
2009 report also conveyed some demographic information about Hartford’s public school 
students. Ninety-two percent of students in the Hartford Public Schools qualified for free 
or reduced lunch, reflecting the city’s overall low per capita income. Forty-three percent 
of students lived in households where English was not the primary language, and 14% of 
students started school in 2008 without being fluent in English.102 These statistics reflect 
the unique characteristics of the city of Hartford and its population that needed to be 
taken into consideration while formulating this study’s methodology. 
HPV in Connecticut 
In Connecticut, HPV is not a reportable disease, so there is little data on state 
incidence or prevalence rates. However, the Connecticut Department of Public Health 
(CT DPH) does track cervical precancerous lesions, which can be used as a surrogate 
marker for infection.104 HPV-related cervical intraepithelial neoplasia grades 2 and 3 
(CIN 2/3) and adenocarcinoma in situ (AIS) were added to the reportable diseases and 
laboratory reportable significant findings lists in Connecticut in 2008.104 Pathology 
laboratories in the state reported 3,702 cases of CIN2/3 and AIS in 2008, representing 
2,999 individual women.104 The majority of cases had a diagnosis of CIN 2, while only 
1% were diagnosed with AIS.104 Data have also demonstrated an overall statewide 
incidence rate of CIN 2/3 and AIS of 212 cases per 100,000 females, aged 15 and over. 
The highest rate was found in New London County, of 292/100,000 females, while 
Windham and Tolland counties had the lowest rates of 161 and 162/100,000 females, 
respectively. Hartford County had a mid-range rate of 180 cases per 100,000 females.104 
State trends regarding age distribution of infection reflected national trends, with young 
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women being disproportionately affected. In 2008, females between the ages of 18 and 
29 had the highest incidence rate of infection, with a rate of 706/100,000 and a total of 
1,658 cases, while those older than 50 had the lowest incidence rate, of 36/100,000.104   
As part of the analysis for a report published in the Morbidity and Mortality 
Weekly Report (MMWR) on April 20, 2012, the CDC calculated rates and actual counts 
of HPV-associated cancers by state. Again, Connecticut state trends reflected national 
trends. Of all HPV-associated cancers, cervical carcinoma had the highest incidence rate 
(6.13/100,000).105 Oropharyngeal SCC had a rate of 6.09 cases/100,000 in men, but only 
1.30/100,000 in women. The rates of anal SCC were low for men and women, 1.14 and 
1.64/100,000, respectively. Vulvar SCC, vaginal SCC, and penile SCC all had incidence 
rates of less than 2 per 100,000 individuals.105 
The National Immunization Survey estimates the rate of HPV vaccination 
coverage among adolescents aged 13-17, by sex and by state. Based on this survey, in 
2013, the estimated vaccination coverage for girls in Connecticut was 56.0% for the first 
dose, 49.0% for the second dose, and 40.1% for the third dose. The percentage of females 
who received three doses among those who had at least one HPV dose was 78.4%. 
Regarding males, the coverage for the first dose was 52.3%, 36.4% for the second dose, 
and 23.4% for the third dose. The percentage of males who received three doses among 
those who had at least one HPV dose was 66.0%.106 A literature search regarding HPV 
vaccine uptake in the city of Hartford did not reveal any public data, so a complete 
picture of vaccination status among Hartford’s youth is not known. Secondary data were 
collected from Carol Steinke, RN, BSN, the Public Health Nursing Supervisor at the City 
of Hartford’s Department Health and Human Services (DHHS) (email communication, 
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February 2014). She provided estimates regarding the HPV vaccination coverage rate 
among those attending the DHHS STD Clinic in Hartford. Data from the start of tracking 
in 2012 to 2014 revealed that the Gardasil vaccine series had been started on 234 
individuals, of which 68%, or 158 individuals, were females, and 32%, or 76 individuals, 
were males. Of these 234 individuals, 56%completed 2 doses, while 29%completed the 
full series. 
These low coverage rates likely reflect the fact that there is currently no HPV 
vaccine mandate in the state. In the 2006-2007 state legislative session, three bills were 
introduced regarding the HPV vaccine. HB 5485 proposed to cover the 3-dose vaccine 
series under the state’s HUSKY plan for girls aged 11 to 18 years. This bill was sent to 
the Senate Appropriations Committee, where it was approved. HB 6085 proposed to add 
the HPV vaccine to the adolescent vaccine schedule, as well as create an outreach 
program to educate the public about cervical cancer and the vaccine. This bill was 
referred to the Joint Committee on Public Health, but did not leave the committee. 
Finally, HB 6977 would have implemented a HPV mandate for all girls in the state 
entering the 6th grade, but was also not approved. Since then, no other legislation has 
been introduced in the state regarding HPV.64 
As with HPV vaccine uptake, a literature search regarding the level of knowledge 
and attitudes about HPV and its vaccine among those residing in Hartford reveals very 
little public data. One study was conducted among Connecticut-licensed pediatricians in 
2008 to investigate practitioner acceptability of the HPV vaccine, which found that 
pediatricians with greater self-reported knowledge about HPV were more likely to have 
discussions about sexually transmitted infections with their patients.107 However, this 
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study was conducted prior to the routine recommendation of the vaccine for boys, and did 
not investigate attitudes among individuals actually receiving the vaccine. Additional 
epidemiological data are now coming from the Connecticut Emerging Infections 
Program, which is a joint project between the CT DPH and the Yale University School of 
Public Health. Enhanced surveillance for CIN 2/3 and AIS among women between 18 
and 39 years old living in New Haven County is expected to continue for the next 10 
years, and will hopefully allow for monitoring of the impact of the HPV vaccine.104 
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Chapter 3: Methodology 
The project from which the data in this thesis were drawn was conducted by a 
group of 12 students who participated in the required practicum course in the 
Winter/Spring semester of the University of Connecticut’s Master in Public Health 
program. The project was conducted in collaboration with the City of Hartford’s 
Department of Health and Human Services (DHHS). 
Key Informant Interviews 
This project was initiated with an informal meeting with the Executive Assistant 
to the Director of the DHHS who briefed the group about the organization and provided 
suggestions for contacts in Hartford to reach parents and adolescents. Subsequently, 
information was gathered from the Public Health Nursing Supervisor at the DHHS on the 
approximate vaccination coverage rate of Hartford’s youth, as no formal data have been 
published to date. Data from the start of tracking were provided from the City of 
Hartford’s DHHS STD clinic and are presented in Chapter 4. These secondary data 
provided the only data regarding vaccine uptake in Hartford that was acquired during the 
course of this project. 
 Contacts were made at the National Black HIV/AIDS Awareness Day 
Community Fair in Hartford on February 7, 2014. Individuals were approached at their 
respective booths, at which time the goals of this study were described. A brief 
presentation regarding HPV and the HPV vaccine, vaccine uptake, and suspected 
facilitators and barriers to vaccination was given to those who wanted more information. 
It was explained that one of the aims was to pilot test a didactic presentation with groups 
of parents and adolescents, after which the opportunity to participate was offered. 
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Physician Interviews  
Semi-structured key informant interviews with physicians were also conducted 
(see physician interview protocol in Appendix I). These sessions were held to document 
the knowledge and attitudes of family physicians on HPV and the HPV vaccine, in 
addition to the factors that influence physicians’ decisions to recommend the vaccine, 
who physicians recommend the vaccine to, and how physicians deal with negative 
responses from parent figures. An interview protocol was developed that contained 
questions covering the domains previously mentioned. The first section specifically 
addressed physicians’ patient panels, asking such questions as “What percentage of your 
patients does not have health insurance?” and “If you had to estimate, what percentage of 
your patient panel are white, Black, Hispanic, or Asian?” The second section assessed 
physician practice, in an attempt to understand the opinions of HPV vaccination in their 
patients, as well as barriers to vaccination in their population. Physicians were asked if 
they offered the HPV vaccine to their patients. Open-ended questions followed, such as 
“Could you describe how you presented the vaccine to your last patient, and how you 
described it to the adolescent and/or parent?”, “Could you give an example of a specific 
patient or parent that initially refused the vaccine and then changed their views when you 
discussed the reasons for the vaccine?”, and “Do you think your input as a physician can 
change someone’s mind from refusing the vaccine?” The final section assessed physician 
knowledge, and asked such questions as “Do you think that the HPV vaccine is 
effective?” and “Do you have any concerns with giving the vaccine to your patients?” A 
final question attempted to draw out recommendations to increase uptake, asking what 
could be implemented or changed to increase vaccination rates in Hartford. 
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A total of six physicians were interviewed, either by phone or in person.  With 
assistance from other students and faculty members of the Master of Public Health 
program at the University of Connecticut, contact was initiated with various physicians 
throughout the greater Hartford area. Those contacted practiced in the Hartford area, or 
provided the majority of their services to Hartford residents. Purposive, non-random 
sampling of physicians was conducted: interview appointments were made with those 
that responded to the initial contact, based on mutual schedule availability. Other factors, 
including the racial, gender, and socioeconomic makeup of their patient populations, 
were not taken into account. Physicians were made aware of the project, contacted prior 
to the interview, and interviewed only with their consent. 
Literature Review 
An extensive review of the existing literature was conducted.  Four main topics 
were covered. First, the pathophysiology and biological mechanisms of HPV and the 
HPV vaccine were investigated. Specifically, information was gathered on the 
pathophysiology of HPV, focusing on the differences between the high-risk and low-risk 
strains; symptomatology; the mechanisms involved in the contribution to cervical and 
other kinds of cancer; the associated risk factors for this transition; and the mechanism of 
action of the two vaccines on the market. Epidemiological factors were examined as well, 
specifically looking at the incidence and prevalence of HPV in the United States, 
Connecticut, and Hartford; the distribution of infection by ethnicity and race; and the 
types/cases of cancer associated with HPV. Second, an in-depth exploration was done on 
the history of the HPV vaccine. The differences between Gardasil and Cervarix were 
examined, in addition to the process by which these vaccines were developed and tested, 
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the process of FDA approval, the evidence used to support efficacy and safety, the profits 
associated with vaccine uptake, and prior and current ACIP recommendations. The 
literature was thoroughly searched for any documented problems with vaccine safety or 
efficacy. Third, current HPV vaccine uptake was studied. The following questions were 
researched: What is the current uptake of the HPV vaccine? Are there any groups that 
have lower uptake than others? What are the barriers and facilitators that impact vaccine 
uptake among these groups? Is there any problem with people completing the series? 
Lastly, policies associated with the HPV vaccine were investigated. Specifically, 
information was gathered on how (and who) introduced the vaccine to the public, how 
public opinion on the vaccine was shaped, and the processes by which the vaccine was 
rolled out to both females and males. Financial issues were examined as well, including 
how the vaccine is funded, coverage under various insurance plans, and pricing of the 
vaccine. Finally, prior and current state mandates were investigated, specifically looking 
at the current situation in Hartford. 
Research Model 
Based on the key informant meetings and literature review, a hypothesized model 
was created that identified factors influencing the intent to be vaccinated among 
adolescents. 
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Figure 1—Research Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dependent Variable: 
Intent to be vaccinated among adolescents 
The dependent variable will assess intent to receive the HPV vaccine among 
Hartford adolescents with a close-ended survey question: “Do you plan on being 
vaccinated in the next year?” Only a “yes” answer will be considered confirmatory; 
failure to answer the question will be considered a lack of intent. 
Independent Variables: 
Parental attitudes  
This domain will examine parental influence on vaccination intent. Specifically, 
through close-ended survey questions and open-ended discussion questions posed to 
adolescents, the role of parental consent as a facilitator of vaccination (and conversely, 
parental refusal as a barrier to vaccination) will be explored. 
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Physicians’ advice 
This domain will investigate physician influence on vaccination intent. Similar to 
the exploration of parental influence, close-ended survey questions and open-ended 
discussion questions posed to adolescents will target whether physician recommendation 
acts as a facilitator to vaccination. Additionally, key informant interviews conducted with 
physicians documented the knowledge and attitudes of family physicians on HPV and the 
HPV vaccine, the factors that influence physicians’ decisions to recommend the vaccine, 
who physicians recommend the vaccine to, and how physicians deal with negative 
responses from parent figures. Physicians were asked what percentage of their patients 
accepts the HPV vaccine. 
HPV and HPV vaccine knowledge 
This domain will examine the knowledge base of Hartford adolescents concerning 
HPV and the HPV vaccine, with a particular focus on perceptions regarding susceptibility 
to and severity of contracting HPV. Additionally, attitudes and beliefs about the main 
barriers and facilitators to vaccination in Hartford will be explored. This will be done 
through close-ended survey questions addressing these issues. Answers to these survey 
questions will be coded as “1” for correct and “0” for incorrect, when compared to an 
investigator-created key. Correct answers will be added up into scales to create a final 
score to quantify knowledge. Overall scores will be compared both before and after the 
implementation of a didactic presentation. Additionally, open-ended discussion questions 
will be posed to expose potential misconceptions regarding HPV and the vaccine. 
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Hypotheses 
Adolescents are at a stage in their life in which they are starting to gain 
independence from their parents and families, but still remain somewhat dependent on 
them to make critical decisions, such as those related to health. Therefore, it was 
hypothesized that: 
(1) The most significant influence on the intent to be vaccinated will be adolescent 
knowledge and beliefs. Knowledge will be positively correlated with the intent to 
be vaccinated.   
(2) Increased knowledge will be associated with the belief that HPV infection is 
serious, as well as that the HPV vaccine is effective. 
(3) Parental knowledge, beliefs, and guidance will significantly influence intent.  
Adolescents with parents and guardians with more negative attitudes regarding 
the vaccine will be less likely to want the vaccine.  
(4) A physician recommendation to be immunized for HPV will positively influence 
both parental and adolescent decision making. 
(5) The majority of adolescents will have heard of HPV and its vaccine prior to 
presentation and focus group discussions. 
(6) Prior to implementation of the educational intervention, adolescents will 
demonstrate a higher rate of misconceptions regarding HPV, than afterwards.  
(7) Belief that the HPV vaccine is effective will be most often identified as a 
facilitator for vaccination, while fear of side effects will be most often cited as a 
barrier. 
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Study Sample 
 This study was conducted with groups of adolescents drawn from various 
community-based organizations, which included Community Partners of Hartford, 
YWCA, Voices of Women of Color, and the DHHS’ Hartford Teen Pregnancy 
Prevention Initiative. Through collaboration with the DHHS, as well as with assistance 
from other students and faculty members of the Master of Public Health program at the 
University of Connecticut, contact was initiated with various organizations throughout 
the greater Hartford area.  Purposive, non-random sampling of groups of adolescents 
were selected by setting up appointments to present the informational tools discussed 
below, based only on the mutual schedule availability of the organization and the 
students.   
Didactic Presentation 
The first objective of this project was to educate adolescents through a brief 
informational session. A 15-20 minute PowerPoint presentation was prepared by the 
practicum team, utilizing topics gathered from the initial literature review and key 
informant interviews. The purpose of this didactic intervention was two-fold. First, it was 
presented to the groups of adolescents recruited from the various community-based 
organizations in Hartford specifically for this study. Second, it was used as a pilot test, 
and, once modified based on feedback from this study’s participants, can be used to lay 
the groundwork for a future larger HPV awareness project in Hartford. Various students 
from the 2014 Spring semester practicum team, as well as one student from the 2014 
Summer semester practicum course, conducted these presentations.  
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Principles from the rational model, the health belief model, the extended parallel 
process model, and the theory of planned behavior, as described in Chapter 1, were 
merged used to create the presentation utilized in this study. The presentation began with 
a brief anecdote about a teenager diagnosed with Stage 1A cervical cancer, adapted from 
a true story on a cancer support website (https://www.fightlikeagirlclub.com). This 
anecdote was followed by a description of HPV, covering transmission and potential 
consequences of infection, including the link to various malignancies. Images were 
displayed to illustrate the many ways HPV infection can present in the body. Previous 
studies have shown that HPV is often confused with herpes simplex virus (HSV) and 
human immunodeficiency virus (HIV), so the differences between these three viruses 
were described. Then, a description of the process by which HPV leads to cancer was 
provided. After addressing this basic information, the presentation attempted to rectify 
common misconceptions associated with HPV. It was explained that both males and 
females can be infected and that there is no cure for infection, though most infections are 
cleared by the immune system without intervention. Additionally, the seriousness of 
cervical cancer was emphasized. 
The presentation then led into a description of the HPV vaccine, which included 
the differences between Gardasil and Cervarix, the dosing schedule, its mechanism of 
action, and its target population. As with HPV infection, common misconceptions 
associated with the vaccine were addressed and corrected. It was emphasized that an 
individual does not need to be sexually active to receive the vaccine, that the vaccine only 
prevents (and does not cure) infection, and that even if one remains abstinent until 
marriage, the vaccine is still important. It was explained that both males and females can 
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get the vaccine, and that the vaccine has been proven to be safe and effective, without 
known serious adverse reactions. This was followed by a brief note about the cost of the 
vaccine, and various options for financial assistance for those uninsured. The presentation 
ended with a suggestion for participants to talk to their physicians about receiving the 
vaccine.  
Pre/Post-Surveys 
To assess the impact of the presentation, a survey instrument was developed to be 
administered to adolescents both before and after the didactic presentation (see survey 
instrument in Appendix II). Questions were developed based on identified gaps in 
knowledge and common misconceptions gathered from the initial literature review and 
key informant interviews. The three-page survey instrument consisted of 25 primarily 
close-ended, multiple choice questions, addressing each of the factors identified in the 
initial research model.   
The survey was distributed to a total of 75 adolescents twice, both before and 
after the PowerPoint presentation was administered, for a total of 145 responses. The 
student investigator of the study, or another student from the practicum team, delivered 
the survey instrument and explained the study goals, asking participants to answer each 
question to the best of their knowledge. However, the final sample involved multiple 
incomplete surveys. Additionally, while there were 75 pre-presentation surveys collected, 
there were only 70 post-presentation surveys returned. 
The survey was initiated with questions addressing one of the three dependent 
variables in the initial research model, HPV and HPV vaccine knowledge. Three single-
answer, multiple choice questions were first asked to establish the level of pre-existing 
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knowledge about HPV. Namely, respondents were asked whether they had ever heard of 
HPV, what they thought HPV is, and what they thought the most common STD is. This 
was followed by a multiple-choice question, asking respondents to circle any condition 
they thought HPV could cause. Answer choices included correct choices such as cancers 
of the reproductive system for women and genital warts, as well as incorrect choices such 
as AIDS and breast cancer. The presence of common misconceptions was then tested 
through true or false questions. Examples of question stems were, “You would always 
know if you had an HPV infection,” “Antibiotics can cure HPV,” and “If you wait to 
have sex until after marriage, you cannot get HPV.” More specific questions testing 
knowledge were also asked, including a fill-in question asking respondents to fill in the 
age at which HPV vaccination can start, and a question inquiring about the number of 
vaccine doses needed to complete the series. A key was created with the correct answers, 
and compared to participants’ responses. Correct answers were added up into scales to 
create a final score to quantify knowledge for each participant; overall performance was 
compared before and after the presentation. 
Two questions focused on attitudes towards HPV and its vaccine, and were not 
counted towards the final “knowledge score.” These were true or false questions, with the 
statements “HPV infection is serious” and “The HPV vaccine is effective in preventing 
HPV infection.” The relationship between the intent to be vaccinated and these question 
responses was tested. Two other questions (multi-answer, multiple choice) attempted to 
gain a better understanding of barriers and facilitators to vaccination. These addressed the 
independent variables of parental attitudes and physicians’ advice in the initial research 
model. The first question asked respondents to identify why a teenager would decide to 
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get vaccinated, assessing potential facilitators. Choices addressed both parental input 
(“His/her parents told him/her to”) and physician input (“His/her doctor told him/her to”), 
as well as personal beliefs (“To prevent HPV infection” and “To prevent cervical 
cancer”). The second asked respondents to identify reasons a teenager would decide not 
to be vaccinated, assessing potential barriers. Choices again included parental input 
(“His/her parents did not tell him/her to” and “His/her parents did not want him/her to”) 
as well as personal beliefs (“Thinking that the vaccine is unsafe,” “Fear that the vaccine 
will cause pain,” and “Cost of the vaccine”). For both of these questions, respondents 
were encouraged to circle all choices that applied. Again, the relationship between the 
intent to be vaccinated and responses to these questions was tested. 
Finally, the dependent variable of the initial research model, vaccination intent 
among adolescents, was addressed with a yes/no question, which inquired, “Do you plan 
on being vaccinated in the next year?” 
Focus Group Discussions 
Following each informational presentation and administration of the post-
presentation survey instrument, brief, semi-structured discussions were conducted with 
those adolescents in attendance (see question guide in Appendix III). The purpose of this 
activity was twofold. First, it was an opportunity for those in attendance to offer 
suggestions, recommendations, and cautions regarding the content and style of the 
didactic presentation. Second, it allowed the student investigator to gather more in-depth 
information on misconceptions and ideas about HPV, attitudes about vaccination, and 
perceived barriers and facilitators to vaccination.   
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 Each session was initiated by a description of the purpose of the focus group, as 
well as instructions for how to answer the posed questions (e.g. “The group is not trying 
to reach an agreement; you may disagree with others as long as you do it in a respectful 
manner”). Reassurance was provided that participants could leave the discussion at any 
time, and that all dialogue would remain confidential, without being linked to names or 
other personal information. Questions regarding the presentation itself inquired about 
ways to improve the presentation and examples of content that could be added, revised, 
or removed. Questions about HPV and its vaccine addressed: (1) barriers to vaccination, 
(2) motivating factors for vaccination, (3) series completion, (4) vaccination in males, 
and (5) sources of information about HPV and its vaccine. 
Statistical Methods 
Quantitative data analysis was performed using SPSS 22.0. Descriptive statistics 
including frequencies, percentages, means, medians, and modes were analyzed for each 
question in the survey instrument. Frequencies were generated for the adolescent study 
sample, sorted by pre-presentation (n=75) and post-presentation (n=70) responses for 
each question. Answers to all knowledge questions were coded as “1” for correct and “0” 
for incorrect, as compared to an investigator-created key. Correct answers for the 
questions assessing knowledge were added up into scales to create a final score 
summarizing knowledge for each participant. Overall performance among participants 
was compared before and after the presentation. Relationships between bivariate 
categorical variables were tested using Chi-Square, while T-tests and one-way ANOVA 
were utilized for associations between categorical and continuous variables. Results were 
considered significant with a p-value less than or equal to a significance level of 0.05. 
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Qualitative data analysis of the adolescent focus group discussions and the 
physician interviews were performed using Atlas.ti, a computer based analytical tool 
designed to identify primary themes in qualitative textual data.108 Five primary codes 
were created for the adolescent group discussions surrounding major themes and 
included: knowledge; barriers; misconceptions; facilitators; and presentation 
improvements. Discussions were then systematically reviewed and codes were assigned 
to quotations and dialogues covering each of the five codes. Atlas.ti was then used to 
generate query reports surrounding each of the major codes. Query reports were reviewed 
and major themes were extracted. The same was done for the physician interviews. In this 
case, eight primary codes were created, which included: physician characteristics/patient 
demographics; estimated HPV coverage rates; HPV vaccine acceptance and physician 
practice; physician knowledge; insurance/cost issues; patient barriers; physician barriers; 
and recommendation.   
IRB Exemption 
This project received exemption status through the University of Connecticut 
Health Center Institutional Review Board (UCHC IRB). No identifying or personal 
information, such as names, past medical history, or vaccine status, were gathered from 
study participants.   
Notes from the focus group sessions were recorded either by a scribe in a Word 
document, or by tape recorder when allowed. The scribe anonymously documented the 
participants’ responses and input in the discussion. No names or other personal 
identifying information were included; individual responses were labeled P1, P2, etc. (i.e. 
Participant 1, Participant 2). The group members were asked not to use his or her own or 
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anyone else’s name in the discussions. If names were used, they were not recorded in the 
Word document, or were removed from the record post-discussion. 
Physician interview sessions were also recorded, and later transcribed into a Word 
document. Practitioners’ responses were anonymously documented, labeled as P1, P2, 
etc. (i.e. Practitioner 1, Practitioner 2). The practitioners were asked not to use their, or 
anyone else’s, name in the discussion. No names or other personal identifiable 
information were included in the transcripts. If names were used, they were not recorded 
in the Word document.  
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Chapter 4: Results 
Key Informant Interviews 
Discussions were held with representatives from various organizations at the 
National Black HIV/AIDS Awareness Day Community Fair in Hartford on February 7, 
2014. Attending the Fair provided a sense of how key stakeholders in the community felt 
about HPV and the vaccine at the onset of the study. Most individuals approached during 
the fair, including a service coordinator for Community Health Services, the mentoring 
program director from True Colors: Sexual Minority Youth and Family Services, and 
volunteers from Hands On Hartford, agreed that infection with HPV is a serious issue, 
and that the vaccine is an effective preventive strategy. The general consensus was also 
that the vaccine is under-utilized, particularly among the youth of Hartford, often due to 
parent distrust/refusal of the vaccine. An epidemiologist from the STD Control Program 
at the Department of Public Health expressed his belief that poor HPV vaccine uptake 
among adolescents is one of the biggest unresolved public health issues in Hartford.  
Every group represented at the fair was approached, at which time the goals of 
this study were described and the opportunity to participate was offered. Most groups, 
including Community Health Services, True Colors, and Planned Parenthood, were 
highly interested in the project, providing their contact information for further 
communication. One religious-based program expressed reluctance to support this 
study’s goals by setting up presentation groups with adolescents and parents, citing an 
abstinence-only educational policy.   
Key informant interviews were also conducted with six physicians from the 
Hartford area. 
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Physician Characteristics / Patient Demographics 
 Two physicians were pediatricians, whose patient panels were entirely made up of 
children under the age of 18 years. Another physician was an obstetrician/gynecologist, 
whose patient panel consisted of females over the age of 13 years. Twenty to thirty 
percent of this doctor’s patients were reported to be under the age of 18 years. Three 
family medicine physicians were also interviewed, who reported that children under the 
age of 18 years made up 10% to 45% of their patient panels.  
 These healthcare providers had racially diverse patient panels, consisting of large 
proportions of racial minorities. Overall, patient panels consisted of ranges of 10% to 
30% Caucasians, 10% to 40% Hispanics, and 20% to 80% African Americans. Asian 
patients represented a small minority, ranging from 5% to 10% of total patient 
populations. Most of these patients were reported to be Hartford residents. Hartford 
residents made up a majority of the patient panels of four physicians, ranging from 80% 
to 90%. Another physician reported that half of his patients were from Hartford, while the 
last related that approximately one-third of his patients were from the Hartford area.   
Estimated HPV Coverage Rates 
Physicians were asked to estimate the rates of vaccine coverage in the United 
States (“If you had to guess, in the United States, what percentage of adolescent females 
have received one shot of the vaccine? And what percentage has received the complete 
three-shot series?”). Reponses were fairly accurate based on current female vaccination 
rates in the United States. Physicians estimated that 30% to 60% of patients received one 
vaccine, and that 15% to 40% have received the full three-dose vaccine series. In 2013, 
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the CDC reported that 57.3% of females aged 13-17 had received at least one dose of the 
HPV vaccine and 37.6% had completed the 3-dose series.66   
HPV Vaccine Acceptance and Physician Practice  
Most physicians said that if offered the vaccine during a visit, the majority of 
patients accept. One physician stated that approximately half of his patients accept the 
vaccine, while four others responded that 80% to 90% of their patients accept it. The final 
physician approximated an acceptance rate of 65%, reporting that many of his patients 
and their parents wanted to wait until they were older to start the series. When asked, 
“What percentage of patients offered the vaccine accept the vaccine?” he responded: 
They accept. More and more, they have accepted more. The 
majority of patients accept it. But I think that about 25-35% refuse. 
I have a lot of them, like 30-35% that say, “I won’t do it today, 
how about you do it next time? 
 
All six physicians said that they offer the vaccine to their patients as part of 
routine health maintenance. The five physicians whose patient panels consisted of both 
female and male patients said that they offered the vaccine to both genders between the 
ages of 9 and 26. However, most reported that vaccination was most heavily promoted 
around the age of 11 years:  
In our clinic, we start telling parents about the vaccine at the age 
of 9. Starting when they reach adolescence, that’s when we start 
asking them to get the vaccine, usually around the age of 11 or 12. 
 
When offering the vaccine, most reported that they emphasized the efficacy of the 
vaccine, highlighting the protection it offers against cervical cancer and genital warts. 
Those that see male patients also reported talking about its efficacy against penile cancer 
and genital warts in boys.  
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Well I always tell people that this vaccine is available for 
protecting them against the HPV virus, it’s a series of three shots, 
HPV can be a precursor to cervical cancer later on, and even if 
they have been exposed to HPV in the past, this can protect them 
from the strains that they have not been exposed to. And then, I tell 
them anyone who is sexually active could have been exposed to 
any of the HPV viruses.  
 
The obstetrician/gynecologist responded that most of her younger patients are 
pregnant and have to wait until after pregnancy to receive the vaccine. This physician 
also mentioned that she does not try to change a patient’s mind if the vaccine is refused.  
If a patient says, ‘No, I do not want it,’ it’s not just that they don’t 
like it, they just don’t want it.  I do not argue with them. 
 
 Another physician reported that an opt-out system was utilized in her office, 
where the standard practice is to routinely offer patients the vaccine, but allow them (or 
their parents) to decide to refuse the vaccine: 
We usually default to the patient. We kind of tell them that they are 
going to get the vaccine and they would have to choose to refuse it. 
[They would have to opt out?] Yes, they would have to opt out of it. 
[Is that standard for the entire practice?] Yes, that is standard for 
the entire practice.  
 
Physician Knowledge of the HPV Vaccine 
 Four out of the six physicians who participated believed in the efficacy of the 
HPV vaccine. One mentioned concerns that it has not been proven to be effective against 
cervical cancer or genital warts, and only offers it because it is recommended. This 
physician also reported that only one third of her patients have received the HPV vaccine.  
I don’t fully believe that it’s been proven to be effective, so I have a 
hard time being 100% behind it. I offer it because I am supposed 
to… I don’t believe that it has been in existence long enough to 
know whether it is effective or not. [Do you think it’s effective 
against genital warts?] No, the purpose of it is to help prevent the 
high-risk HPV’s, the ones that can lead to cancer. 
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 The sixth physician expressed concern that the vaccine is relatively new. One of 
the four that expressed confidence in the vaccine stated that he felt more time is 
necessary to see decreased rates of genital warts and cervical cancer. When asked, “Do 
you think that the HPV vaccine is effective?” he responded: 
I think so. I think we do not fully know yet but we will see in 
another one to two decades. We will see if the incidence of cervical 
cancer and genital warts decreases in one to two decades. 
 
Insurance / Cost Issues 
The percentage of uninsured patients among the physicians’ patient panels was 
low, with all six reporting a percentage less than 10%. As a result, cost did not seem to be 
a major barrier to vaccination, as it is covered under most private and public insurances. 
Five out of six physicians agreed that cost was not an issue, and one reported that it was 
an issue only for self-pay patients. One physician described how the Vaccines for 
Children (VFC) Program covers the costs for those uninsured. When asked, “Is cost a 
barrier to vaccination in your patients?” she responded,  
Not usually because almost all of our patients get their vaccines 
through the VFC program… It’s now covered actually even for the 
commercially insured under the VFC program, but I’m not 100% 
sure on that. So initially there might have been some wariness 
about that but it has not been a big factor for us. 
 
Two physicians reported the breakdown of insurance types for their patients, both stating 
that around 60% to 80% are covered on Medicare or Medicaid, with the rest on private 
insurance. One mentioned the availability of Husky Health insurance (the State of 
Connecticut’s public health coverage program providing free or low-cost health care for 
Connecticut kids and teens) for children whose parents are uninsured: 
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I have a large percentage of people, I would say around 60%, who 
are covered on Medicare or Medicaid. For kids, they’re covered 
with Husky insurance, which is like Medicaid. 
 
Patient Barriers 
When questioned about barriers to vaccination, common themes emerged. When 
the physicians were asked, “What are some other reasons that patients or their parents 
have refused the vaccine?” most stated that teenagers do not like receiving needles. Some 
indicated that a small percentage of their patients are completely anti-vaccine. The 
majority cited a fear of side effects as a major barrier. As one physician reported:  
Some people do not believe in vaccines, but I do not have many of 
these. Some people already had the vaccine, but some people have 
heard stories. It could be hearsay, but they do not want to get 
vaccinated because of those reasons.  
 
 Some stated that it was difficult to recommend the vaccine without a school 
entrance mandate. One physician noted that parents of his patients easily accept a vaccine 
that is necessary to enter school, but are wary of any additional vaccines.  
Sure, we do tell them [parents] that it’s not one of the required 
vaccines for school so that differentiates it from the rest. That gives 
them an option to refuse it and still send their children to school.  
 
 All six physicians reported deflecting concerns that vaccinating against HPV may 
increase sexual activity or lower the age of the initiation of sexual activity. As one stated: 
Sometimes I get parents who just don’t want to give the vaccine to 
their kids. Lots of parents are scared that they’re giving a vaccine 
that might make their kids more sexually active, or have sex at an 
earlier age, but I think that it’s a good idea to give the vaccine 
before they’re sexually active and before they’re really aware of 
what sex is. Like, the Hepatitis B shot in children. We give that to 
every kid after they’re born, and it prevents a blood-borne 
infection. I don’t think that it makes people more likely to use IV 
drugs, and I really don’t think that giving an HPV shot will make 
people more likely to have sex at a younger age.  
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Many parents refuse the vaccine because their children are not sexually active. However, 
as the physician above stated, vaccination is best started at an age before sexual activity, 
as it is a preventive tool. One physician replied that at the age of 9 or 10 years, it may be 
hard to convince a parent to accept the vaccine. When their children are in the early 
adolescent stage, around 11 or 12 years, they become more open to vaccinating their 
children.  
If you start offering it at 11, 12, 13, 14, I think their parents 
are already scared of sexual activity, so they’re more used 
to the idea, and they’re like “Yes, please give it to them!” 
[Yes, there’s a big difference between a 9 and 12 year old].  
Yes. Exactly. 
 
One physician provided an example of a specific patient: 
 
I had one parent who refused the vaccine because she thought that 
we should wait until her daughter was older. For some parents, 
it’s hard to see their little girl and think about giving them a 
vaccine that prevents against a sexually transmitted disease… For 
some parents, it’s really hard to accept that their kid may choose 
to have premarital sex, especially for traditional families. So I 
basically told her that it’s best to get it at this age, so that 
whatever age she chooses to become sexually active, she’ll be 
protected, and mom seemed to think that was reasonable.  
 
It appears that some patients do not believe that they need the vaccine. One 
physician reported a case where a patient, who refused the vaccine every year since the 
age of 10, developed genital warts at the age of 17, and then asked for the vaccine. The 
patient apparently asked for the vaccine in the hopes of curing her genital warts. The 
physician described the situation:  
I do have one kid that comes to me who at 17 came in with genital 
warts for the first time, and every visit from her ten year old visit 
on, had been offered the vaccine, initially her guardian refusing on 
her part and then she refusing.‘Til she came in with genital warts, 
and then she said ‘I’ll take the vaccine now.’ And we gave it to her 
because there are different serotypes, but they just couldn’t believe 
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before that they would really need it.   
 
Misconceptions such as these among patients appeared to be common. One physician 
expressed a belief that the number one reason for low vaccination rates is a lack of 
information, and not understanding the importance of the vaccine:  
The number one reason is lack of knowledge because they do not 
understand the importance of the vaccine or the reason to have it 
at all. They do not understand that HPV can lead to cancer. So I 
would say the number one reason is lack of information.  
 
 Those treating males described gender-specific barriers as well. The HPV vaccine 
is often described as the “Cervical Cancer Vaccine,” leading parents to believe that there 
are no perceived benefits from vaccinating boys. One physician described the trouble in 
convincing parents of boys to accept the vaccine: 
I think it’s because a lot of parents think that it’s an exclusively 
female disease. I tell them about penile and anal cancers that can 
develop in men. However, I have to admit that penile cancers are 
pretty rare. And most men who develop anal cancer are gay, so 
that’s a tough sell to parents to talk about the chances that their 
kid might be gay, so we should protect them from anal cancer as 
well.  
 
However, many physicians reported talking about the benefits for female partners: 
  
[H]onestly, if I had to vaccinate my sons, I would give it to them 
just to protect their sexual partners. I think that by giving it to 
boys, you can prevent the boys from giving it to more girls, and it 
would make the vaccine much more effective than just giving it to 
half of the population.  
 
Physician Barriers 
 Most physicians reported that they did not have any specific concerns 
administering the HPV vaccine. They reported warning their patients about the routine 
side effects associated with any vaccination, including pain on injection and bleeding. 
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However, one physician reported that the reports of neurological side effects made her 
wary, despite the lack of evidence of severe adverse effects in the literature:  
I personally heard of stories where girls have had neurological 
difficulties after receiving the HPV vaccination, so I have a hard 
time being 100% behind it. I don’t want to cause more problems 
than I am healing. 
 
 One physician reported concerns that her patients were not receiving all three 
doses within the recommended time frame, and therefore not receiving optimal protection 
from the vaccine.  
Yes, my concern is that the most effective way to give the vaccine is 
to get all three shots in one year. If you lose patients to follow up, 
I’m worried that they won’t get the full course of the vaccine or 
they won’t get it in time and therefore the vaccine would not work 
as well as it should. 
 
Recommendations 
 Three out of the six physicians expressed their belief in the importance of an 
education program for their patients to increase knowledge of HPV and its vaccine. One 
indicated that the education program should target both teens and parents, and stated: 
I think that we need more education. Some people have heard of it 
[HPV vaccine] but don’t know what it’s for or what the purpose is 
and what the health outcomes are. So I think that we need a lot 
more education. 
 
Two physicians said that a school mandate was needed to increase vaccination 
rates. The schedule for the vaccine, with three shots given over a six month period, can 
be difficult in pediatric patients, especially since they may have to miss school for their 
appointments. Additionally, since pediatric patients are used to seeing their pediatricians 
only annually or biennially for well-child check-ups, many miss their follow-up 
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appointments for the second and third shots. One physician argued that if the vaccine was 
made mandatory to enter school, rates of vaccination would increase. When asked, “What 
do you think can be implemented or changed to increase the rates of HPV vaccination in 
Hartford?” she replied,  
School. If schools make it mandatory then they [teens] cannot get 
into school without it. That helps a lot, because parents would 
come in to get the vaccine, and the nurses at school would remind 
them. 
 
Another physician believed that the vaccine should be administered at school for easier 
follow-up:  
If it were offered in school, it would be a lot easier because they 
don’t have to miss a day, or the parent doesn’t have to remember 
to take off from work, or whatever to come back for the other 
vaccines. 
 
Another possible solution proposed was an automatic letter sent to the patient as a 
reminder to come in for the follow-up doses of the vaccine. Two physicians specifically 
reported that in their clinics, this was not done. One speculated on a solution for his own 
clinic:  
The other thing would be, I don’t know, maybe for a system to 
remind them in six months to come back to get their third vaccine. 
I don’t know if we should send out a letter or an automatic 
notification. The ideal thing is that the doctor will send out a letter 
saying, “You are missing the third vaccine, come back to get it 
done.”  
 
A final recommendation was made regarding the current ACIP-recommended 
vaccination schedule of three doses, given within 6 months. One physician stated that the 
three dose schedule is difficult to keep in young, healthy adolescents who only rarely see 
their physicians. Therefore, he recommended that more research be done to determine if 
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one vaccine is effective enough, or if the vaccine can be given yearly with the same 
efficacy to make administration easier:  
I know it’s now being looked at to see if one shot actually might 
actually be enough… the studies done to determine whether it is 
effective is only based on a specific schedule that they decided to 
try. Other dosing schedules could make some scientific sense. 
 
Quantitative Analysis: Pre/Post-Surveys 
General Information  
Adolescent respondents were drawn from community organizations in the city of 
Hartford: Community Partners of Hartford, YWCA, Voices of Women of Color, and the 
DHHS’ Hartford Teen Pregnancy Prevention Initiative. 
Table 1—Participants by Session 
Session Number Pre-Presentation Surveys # 
(%) 
Post-Presentation Surveys # 
(%) 
1 8 (10.7) 8 (11.4) 
2 8 (10.7) 8 (11.4) 
3 10 (13.3) 13 (18.6) 
4 32 (42.7) 25 (35.7) 
5 6 (8.0) 8 (11.4) 
6 11 (14.7) 8 (11.4) 
Total Sample 75  70  
 
Vaccination Intent 
The dependent variable in the initial research model, the intent to be vaccinated 
among Hartford adolescents, was assessed with a close-ended survey question, “Do you 
plan on being vaccinated in the next year?” At baseline, prior to the presentation, 58 out 
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of 75 adolescents (63.8%) answered in the affirmative.  No statistically significant 
association was found between time of administration of the survey (pre-presentation 
versus post-presentation) and vaccination intent, suggesting that the presentation had no 
effect on intent. 
HPV and HPV vaccine knowledge 
As hypothesized, a majority of adolescents, 73.3% (55) of participants, had heard 
of HPV prior to administration of the survey. There was a statistically significant 
difference from pre-presentation to post-presentation (p=0.010), understandably so, as 
this topic was the focus of the didactic presentation. 
Answers to the survey questions specifically designed to assess knowledge were 
coded as “1” for correct and “0” for incorrect and then added up to create a final score to 
quantify knowledge. The maximum score an individual could receive was 26. Prior to the 
presentation, at baseline, scores ranged from 8 to 23, with a mean of 16.6 and a standard 
deviation of 3.46.  Distribution of scores can be seen in the histogram below:   
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Figure 2—Distribution of Knowledge Scores among Pre-Presentation Survey 
Responses 
 
 
A logistic regression was conducted to determine if knowledge, as quantified by 
this final score, affected the dependent variable, or the intent to be vaccinated. It had been 
hypothesized that the most significant influence on intent would be adolescent 
knowledge. While the direction of change was consistent with the hypothesis, the 
association was not statistically significant either before or after the presentation. 
There was a statistically significant difference in mean performance between the 
pre-presentation and post-presentation responses (p= <0.001), providing evidence that the 
presentation was at least effective in increasing knowledge in the short term. Post-
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presentation, scores ranged from 8 to 26, with a mean of 20.3 and a standard deviation of 
4.47.  Distribution of scores can be seen in the histogram below:   
Figure 3—Distribution of Knowledge Scores among Post-Presentation Survey 
Responses 
 
 
Correct response rates to specific survey questions illustrate the improvement in 
knowledge from before to after the presentation. Participants were first asked “What do 
you think HPV is?” and given five possible answer choices: (1) A common cold (2) A 
skin rash (3) A sexually transmitted disease (4) An infection patients get from hospitals, 
and (5) I don’t know what HPV is. Out of 74 pre-presentation responses, 77.0% answered 
with the correct choice of “A sexually transmitted disease.” There was a statistically 
significant difference between pre-presentation and post-presentation responses 
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(p=0.018), with the percentage answering correctly increasing to 91.4%. A similar 
question inquired, “What is the most common STD?” The frequency of each possible 
response to this question by pre-presentation and post-presentation responses, are 
provided in the table below: 
Table 2—Most Common STD 
Question Pre-Presentation % 
(#) 
Post-Presentation % 
(#) 
P value 
Most common STD    
- HPV 17.8 (13) 50.0 (34) <0.001 
- Chlamydia 34.2 (25) 5.9 (4) <0.001 
- Gonorrhea 5.5 (4) 33.8 (23) <0.001 
- Herpes 13.7 (10) 2.9 (2) 0.022 
- HIV 28.8 (21) 7.4 (5) 0.001 
Total Responses (#) 73 68  
As predicted, there was a statistically significant increase in the correct response, HPV, 
after the presentation. There was a significant decrease in all incorrect responses, except 
for gonorrhea. For unknown reasons, more individuals selected this incorrect choice after 
the presentation than before. 
The next question was a multiple-choice question that asked respondents to select 
conditions caused by HPV infection. Answer choices included correct selections such as 
cancers of the reproductive system for women and genital warts, as well as incorrect 
choices such as AIDS and breast cancer. The frequency of each possible response to this 
question was sorted by pre-presentation and post-presentation responses, provided in 
Table 3: 
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Table 3—Sequelae of HPV Infection 
Question Pre-Presentation 
% (#) 
Post-Presentation 
% (#) 
P value 
What can HPV lead to    
- Cancers of the 
reproductive 
system for women 
56.8 (42) 85.7 (60) <0.001 
- Cancers of the 
reproductive 
system for men 
41.9 (31) 57.1 (40) 0.067 
- Mouth/throat 
cancer 
24.3 (18) 48.6 (34) 0.002 
- AIDS 29.7 (22) 14.3 (10) 0.026 
- Genital warts 35.1 (26) 71.4 (50) <0.001 
- Breast Cancer 9.5 (7) 5.7 (4) 0.398 
Total Responses (#) 74 70  
There was a statistically significant increase in the correct responses from pre- to post-
presentation of “Cancers of the reproductive system for women,” “Mouth/throat 
cancer,” and “Genital warts.” Although there was a slight increase in the response rate 
for the correct answer of “Cancers of the reproductive system for men,” from 41.9% to 
57.1%, it was not significant at the 0.05 level. In future educational interventions, then, a 
greater emphasis is needed on the sequelae of HPV infection in men. There was also a 
statistically significant decrease in the incorrect answer choice of “AIDS” and though the 
response rate for “Breast cancer” slightly decreased as well, it was not significant. 
 The concept that both genders can be affected by HPV and can receive the HPV 
vaccine was also tested. Prior to the presentation, 86.7% of adolescents answered 
correctly that HPV can affect both females and males, which increased to 100% after the 
survey (p=0.002). Though an increase was also seen in the percentage that correctly 
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answered that both males and females can receive the vaccine (87.8% to 94.3%), it was 
not a statistically significant change. 
 Two survey questions assessed knowledge regarding the dosing schedule for the 
HPV vaccine. Pre-presentation, 46.5% correctly stated that 3 doses are required to 
complete the vaccine series. There was a statistically significant improvement from pre-
presentation to post-presentation (p= <0.001), with 80% delivering the correct response 
afterwards. The second question asked respondents to fill in the age at which HPV 
vaccination can start. The mean shifted from 13.8 pre-presentation, to 11.0 post-
presentation, into the correct range of 9-13. 
Misconceptions 
Many of the questions used to determine the final knowledge score served another 
purpose: revealing the presence of common misconceptions regarding HPV and the HPV 
vaccine through true or false questions. The prevalence of misconceptions both before 
and after the didactic presentation was high. The frequency of the correct response to 
each of these questions by pre-presentation and post-presentation responses is provided in 
the table below.   
Table 4—Misconceptions Surrounding HPV and the HPV Vaccine 
 
Question  Pre-Presentation % (# 
Correct /Total Responses) 
Post-Presentation % 
(# Correct /Total 
Responses) 
P value 
Men can get HPV 
from homosexual 
or heterosexual sex 
83.6 (61/73) 89.7 (61/68) 0.286 
HPV is preventable 87.5 (63/72) 87.1 (61/70) 0.949 
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The HPV vaccine 
can prevent genital 
warts 
32.9 (24/73) 63.2 (43/68) <0.001 
The HPV vaccine 
can prevent 
cervical cancer 
47.9 (35/73) 80.3 (53/66) <0.001 
You would always 
know if you had an 
HPV infection 
86.7 (65/75) 84.2 (59/70) 0.684 
You can get HPV 
by not keeping 
yourself clean 
50.7 (37/73) 44.3 (31/70) 0.444 
Antibiotics can 
cure HPV 
50.7 (34/67) 75.0 (51/68) 0.004 
If you wait to have 
sex until after 
marriage, you 
cannot get HPV 
86.7 (65/75) 87.1 (61/70) 0.932 
The HPV vaccine is 
only for adults 
89.2 (66/74) 90.0 (63/70) 0.874 
Only sexually 
active people 
should get the 
vaccine 
78.4 (58/74) 88.4 (61/69) 0.109 
If you get the HPV 
vaccine, you don’t 
need to use 
condoms because 
you’re protected 
from STDs 
86.5 (64/74) 85.3 (58/68) 0.838 
If a teenage gets the 
HPV vaccine, he or 
she will be more 
likely to have sex 
75.0 (54/72) 66.2 (43/65) 0.255 
 
It was hypothesized that adolescents would demonstrate a higher rate of 
misconceptions regarding HPV and its vaccine prior to implementation of the educational 
intervention than afterwards. With the exception of the statistically significant 
improvements seen in the correct response rates to “The HPV vaccine can prevent genital 
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warts,” “The HPV vaccine can prevent cervical cancer,” and “Antibiotics can cure 
HPV,” this hypothesis was not supported. After the presentation, 63.2% of adolescents 
correctly answered that the HPV vaccine can prevent genital warts, compared to 32.9% 
beforehand. The percentage that correctly answered that the HPV vaccine can prevent 
cervical cancer also increased from 47.9% to 80.3%. Finally, three-quarters of 
adolescents correctly responded that antibiotics cannot cure HPV post-presentation, 
compared to 50.7% of adolescents pre-presentation.   
The percentage of adolescents responding correctly to the other questions either 
remained static or trended downwards. For some of these questions, it is likely that the 
high pre-presentation correct response rate led to a lack of significant improvement; for 
example, 86.7% and 87.1% of adolescents responded correctly to the statement “If you 
wait to have sex until after marriage, you cannot get HPV,” and 83.6% and 89.7% of 
adolescents correctly answered that men can get HPV from homosexual or heterosexual 
sex, pre-presentation and post-presentation respectively. However, a significant 
percentage of adolescents continued to endorse common misconceptions post-
presentation—55.7% continued to believe that one can acquire HPV with poor hygiene, 
33.8% believed that the HPV vaccine promotes promiscuity, and 14.7% believed that one 
does not need to use condoms for protection against sexually transmitted diseases after 
HPV vaccination. It is not understood whether this was due to question wording or a 
deficiency in the presentation itself.  These are the key areas that should be targeted for 
increased education. 
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Attitudes and Beliefs 
It was hypothesized that adolescent attitudes and beliefs, along with knowledge, 
would positively influence the intent to be vaccinated. Specifically, it was believed that 
adolescents who believe HPV infection is serious would be more likely to desire 
vaccination, as would adolescents who believe the HPV vaccine is effective in preventing 
infection. Two questions in the survey instrument addressed this hypothesis. These were 
true or false questions, with the statements “HPV infection is serious” and “The HPV 
vaccine is effective in preventing HPV infection.” At baseline, prior to the presentation, 
94.7% agreed that HPV infection is serious. There was no significant change in this 
percentage from pre-presentation to post-presentation. Out of 71 pre-presentation 
responses, 80.3% believed that the HPV vaccine is effective in preventing HPV infection. 
The change from pre-presentation to post-presentation indicated an upward trend to 
91.0% (p=0.073).  
Statistically significant associations were not found between belief that HPV 
infection is serious and vaccination intent, or belief in the efficacy of the HPV vaccine 
and vaccination intent, either before or after the presentation. However, logistic 
regressions were conducted to determine if knowledge, as quantified by this final score, 
affected these beliefs. At baseline, prior to the presentation, for every one unit change in 
the final knowledge score, the log odds of believing the HPV vaccine is effective 
significantly increased by 0.387 (p=0.001).  While the direction of change was consistent, 
increased knowledge was not significantly associated with the belief that HPV infection 
is serious.  After the presentation, for every one unit change in the final knowledge score, 
the log odds of believing the HPV vaccine is effective significantly increased by 0.437 
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(p=0.003), while the log odds of believing HPV infection is serious significantly 
increased by 1.099 (p=0.032). 
Barriers and Facilitators 
Two survey questions attempted to gain a better understanding of barriers to and 
facilitators of vaccination. The first question asked respondents to identify why a 
teenager would decide to get vaccinated, assessing potential facilitators. The second 
asked respondents to identify reasons a teenager would decide not to be vaccinated, 
assessing potential barriers. For both of these questions, respondents were encouraged to 
circle all choices that applied. It was hypothesized that belief in the efficacy of the HPV 
vaccine would be identified as the major facilitator for vaccination, while fear of side 
effects would be cited as the major barrier. The frequency of each possible response to 
these questions by pre-presentation and post-presentation responses is provided in Tables 
5 and 6: 
Table 5—Facilitators of HPV Vaccination 
Question Pre-Presentation % 
(#) 
Post-Presentation % 
(#) 
P value 
What are some reasons a 
teenager would decide to 
get vaccinated? 
   
- His/her parents told 
him/her to 
61.3 (46) 65.7 (46) 0.584 
- His/her doctor told 
him/her to 
64.0 (48) 62.9 (44) 0.886 
- To prevent HPV 
infection 
70.7 (53) 67.1 (47) 0.647 
- To prevent cervical 
cancer 
50.7 (38) 58.6 (41) 0.340 
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- Because his/her 
friends all received 
the vaccine 
32.0 (24) 34.3 (24) 0.770 
Total Responses (#) 75 70  
 
Table 6—Barriers to HPV Vaccination 
Question Pre-Presentation % 
(#) 
Post-Presentation % 
(#) 
P value 
What are some reasons a 
teenager would decide 
NOT to get vaccinated? 
   
- Not knowing where 
to get the vaccine 
53.3 (40) 58.6 (41) 0.526 
- Thinking the 
vaccine is not 
necessary 
57.3 (43) 61.4 (43) 0.616 
- Thinking the 
vaccine is unsafe 
37.3 (28) 42.9 (30) 0.497 
- Fear that the 
vaccine will cause 
pain 
49.3 (37) 58.6 (41) 0.265 
- Cost of the vaccine 50.7 (38) 60.0 (42) 0.259 
- His/her parents did 
not tell him/her to 
44.0 (33) 48.6 (34) 0.581 
- His/her parents did 
not want him/her to 
33.3 (25) 37.1 (26) 0.631 
Total Responses (#) 75 70  
As can be seen from Table 5, the most common response to why an adolescent 
would receive the HPV vaccine was “To prevent HPV infection,” both before and after 
the presentation (70.7% and 67.1%, respectively). The least common reason cited was 
“Because his/her friends all received the vaccine” (32.0% pre-presentation and 34.3% 
post-presentation). There were no significant changes seen in response rates from before 
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to after the presentation. The most common barrier cited was “Thinking the vaccine is not 
necessary” (57.3% pre-presentation and 61.4% post-presentation), followed closely by 
“Not knowing where to get the vaccine” (53.3% and 58.6%) and “Cost of the vaccine” 
(50.7% and 60.0%). Though it was hypothesized that fear of adverse reactions would be 
cited as the major barrier, adolescents did not choose “Fear that the vaccine will cause 
pain” and “Thinking the vaccine is unsafe” so often. Again, there were no significant 
changes seen between pre-presentation and post-presentation responses. 
For these two questions, a blank space was also provided to allow for fill-in 
answers. Written responses given for “What are some reasons a teenager would decide 
to get vaccinated?” were: “Incentives at PCP office and at school by nurse,” “Be safe,” 
and “Want to be safe.” Fill-in responses provided for “What are some reasons a teenager 
would decide NOT to get vaccinated” were: “Not aware of the vaccine,” “Don’t know 
about HPV,” “Not sure what it is,” “Danger,” “Against religious beliefs,” and “Scared.” 
One of the independent variables in the initial research model was parental 
attitudes. It was hypothesized that adolescents with parents and guardians with more 
negative attitudes regarding the vaccine would be less likely to want the vaccine. 
However, there was no significant association found between citing parental 
encouragement to receive the vaccine, a lack of parental encouragement, or parental 
refusal and vaccination intent. Another independent variable in the research model was 
physicians’ advice. It was hypothesized that a physician recommendation to be 
immunized for HPV would positively influence adolescent decision making. However, 
once again, there was no significant association between citing physician 
recommendation as a facilitator and vaccination intent. 
83 
 
Qualitative Analysis: Focus Group Discussions 
Five major codes were identified for qualitative analysis of the focus group 
discussions including: knowledge; misconceptions; barriers; facilitators, and presentation 
improvements.  
Knowledge 
The majority of adolescents had heard about HPV previously from a variety of 
sources. The most common response to, “Where have you heard about HPV before 
today?” was school (for example as one participant stated, “My high school gave us some 
information about it”), followed by the doctor’s office (“My doctor told me about it, and 
there were brochures in the doctor’s office”). Other sources included their parents and 
the media (“I heard about it while watching TV”). However, two adolescents did express 
uncertainty about where to receive information about HPV. As one individual from Focus 
Group #4 responded, “How are you supposed to find out about it?” 
Although the majority of adolescents answered positively when asked if they had 
heard of HPV and the vaccine, a major recurring theme throughout discussions was an 
unawareness of cervical cancer and the existence of the Papanicolaou test, more 
commonly known as the Pap smear, as a preventive measure. Five out of the six focus 
groups had questions regarding these topics. For example, an adolescent from Focus 
Group #1 inquired, “What is cervical cancer?” and another from Focus Group #4 asked, 
“I had a question, what’s a Pap smear?” Both “Pap smear” and “cervical cancer” were 
used in the didactic presentation without much explanation, assuming that participants 
had prior knowledge. 
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Misconceptions 
 Questions asked by participants during the course of each focus group discussion 
demonstrated a wide variety of misconceptions. Focus group discussions were held 
following administration of the didactic presentation, meaning that these erroneous 
beliefs remained despite the attempted educational intervention. A major recurring theme 
focused on the false notion that only sexually active individuals can receive the vaccine. 
When asked, “Why do you think the majority of youth have not been vaccinated?” an 
adolescent from Focus Group #1 responded, “Because they are not sexually active,” 
while another from Focus Group #4 stated, “They are not having sex.” 
 Other questions focused on the method of transmission of HPV, providing ideas 
for additional details to add to the didactic presentation. Questions asked include: 
“It says you can get it from skin to skin contact, so what if I touch 
someone on their hair or back or put lotion on them?” 
“Here's a question- can you get it from smoking?” 
“If a guy has it on the lips and the girl kisses him, will the girl get 
it?” 
“Is it something that can run in your family?” 
Finally, when asked, “Do you have any other questions about HPV that we didn't 
answer in the presentation?” a few adolescents asked questions indicating some 
underlying confusion about the differences between HPV and herpes simplex virus 
(HSV), and HPV and human immunodeficiency virus (HIV). One adolescent from Focus 
Group #6 asked about disclosing a positive HPV status to a partner: “Is it illegal to have 
sex with someone if you have HPV and you know that, but you don’t tell the other 
person?” Another adolescent asked about the presence of “sores” with HPV infection, 
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while a third inquired, “If you have HPV, don’t you have to take lots of medication all the 
time?” 
Barriers 
The adolescents were posed this question: “Only 40% of eligible youth have 
received the HPV vaccine. Why do you think the majority of youth have not been 
vaccinated?” In response, participants mentioned a variety of potential reasons. One 
recurring theme was the fear of adverse reactions. The majority cited this barrier as the 
reason for the low uptake rate, as well as the low series completion rate, in Connecticut. 
Reponses by adolescents included: 
“Maybe because they don't like needles; I am scared of needles.” 
“Because they may be scared of what the results are going to be, 
or something from it. They might find out something that they don't 
want to find out. Like side effects from the vaccine.” 
“It probably hurts so they don't want it.” 
 Another recurring theme was a lack of education, and therefore, knowledge. As 
one adolescent succinctly stated, “People don’t know about the complications from the 
virus, so they don’t think it’s [the vaccine] important.” Another responded “There is a 
lack of information about the virus.”  
 When asked what information they learned from the presentation that they didn’t 
know before, adolescents mentioned a variety of key facts related to infection and the 
vaccine: 
“I didn’t know HPV could cause cancer.” 
“I learned that HPV could actually be really bad.” 
“I didn’t know that HPV can have no symptoms.” 
“I didn’t know it was a common sexually transmitted infection.” 
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“I learned that men can get HPV as well.” 
A lack of knowledge among parents was mentioned as a barrier as well. As one 
adolescent in Focus Group #1 stated, “Parents are not talking about it. Some parents 
don't like to talk to their child openly about sex. Parents think that you only need the 
vaccine if you are having sex.”  
Barriers to series completion were also covered. Adolescents were asked, 
“Among girls who receive the first dose, many do not return for the two follow up doses 
– why do you think this is?” The majority of responses addressed the notion that only one 
dose of the vaccine is needed: 
“They think that one vaccination is enough for them.” 
“Maybe because they got one, they think they're OK.” 
“They might think that it's already done and they don't need any 
more shots.” 
“Many people think they are all set, or cured, after the first dose.” 
One adolescent expressed confusion over the three-shot dosing schedule, inquiring, “Why 
can’t you just combine all three shots into one big needle? Why do you need three 
shots?” On the other hand, a number of participants mentioned that a reminder from a 
physician would be helpful in increasing the series completion rate: 
“If someone is in a transition period, like moving, they may not 
have a PCP to remind them to get all the vaccine doses.” 
“People are lazy and forget to go back for the second and third 
time.” 
 
 A major recurring theme throughout the discussion of barriers focused on 
vaccination in males. Participants were asked why they thought the rate of vaccine uptake 
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is so low for boys, especially when compared with the rate among girls. One adolescent 
in Focus Group #6 mentioned the lack of vaccine promotion for males: 
“When I was at the doctor the vaccine was described to me as a 
way to protect my partner, so it made it seem like this whole HPV 
vaccine is geared towards girls and not really for guys. The guys 
are just helping, so they don’t feel like they really need it for 
themselves.” 
 
Another individual from Focus Group #1 expressed a similar sentiment, stating, 
“Because they [boys] really don’t know about it, and haven’t heard of HPV,” while a 
female from Focus Group #4 mentioned, “They [boys] don’t think they have a high risk 
of getting it [HPV].” Additionally, many adolescents believed that males simply see their 
physicians less often, making statements such as “Girls go to the doctor more often,” 
“Guys are embarrassed to go to the doctor,” and “There are no ‘annuals’ for guys.”   
Other gender stereotypes and misconceptions also came into play. For example, a female 
from Focus Group #4 stated, “Because they don’t have a vagina and we do,” mistakenly 
alluding to the view that males cannot get HPV. 
 Two adolescents brought up the fact that there is currently no school mandate in 
place. The HPV vaccine is not a mandatory prerequisite for entrance into school, as many 
other vaccines are. As one stated, “It [the HPV vaccine] is not required, so when it’s an 
option, people don’t do it.” The relatively high cost of the vaccine was also mentioned 
twice, both during Focus Group #4: 
“Some people, they don't have insurance, and they don't have 
enough money to get tested.” 
“Isn't it sometimes because of the money? They might have to pay 
every single time that they come in for it with three doses.” 
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Finally, believing that the vaccine is not necessary and not caring also were mentioned as 
obstacles.    
Facilitators 
Many of the expressed barriers to vaccination were also brought up in the 
discussion of facilitators. When asked what they thought would motivate children and 
adolescents to get vaccinated, participants provided a variety of responses that reflected 
what they felt would be their main barrier(s) to vaccination. Many adolescents expressed 
concern over the cost of the vaccine. Therefore, it was mentioned multiple times that the 
availability of a free vaccine would be a motivator in accepting the vaccine. One 
adolescent inquired, “If I don’t have insurance, can I get it here [school] for free?” A 
school administrator who participated in Focus Group #5 contributed to this topic: 
“If there was no cost to the vaccine, people would be motivated to 
get it. My deductible will end up having me pay a lot of money for 
the vaccine, so if it were me, I would have declined getting it 
before seeing this presentation and knowing all the information.” 
 
A few adolescents also mentioned that they would be more likely to get the vaccine if it 
was required for school entry. As one stated, “If it was required, it would be urgent to 
people, it’s just a suggestion.” 
 A major recurring theme focused on education, particularly a need to better 
educate adolescents about HPV and the availability of the vaccine. A few adolescents 
mentioned that they were more receptive to receiving the vaccine after the presentation, 
as they understood its importance. One adolescent from Focus Group #6 emphasized, 
“Knowing the seriousness of the virus would motivate people to get vaccinated.” Other 
adolescents stated that they were unaware that the vaccine was an option, with a couple 
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specifically mentioning that their physicians had never spoken to them about it. One 
adolescent stated, “Sometimes, like, when they want to have sex, they might not know 
about this [the vaccine], so people should be educated about it a little better.” Finally, 
knowing about the availability of the vaccine itself was cited as a facilitator. “Knowing 
that they can get it anytime” was one response when Focus Group #1 was asked about 
motivating factors.  
Presentation Improvements 
Generally, adolescents were extremely receptive to the didactic presentation. 
When asked what they thought about the presentation, the majority of adolescents 
responded with statements such as, “Great,” “Very helpful,” and “We liked it.” Every 
focus group discussion lasted at least 30 minutes, as participants were eager to provide 
suggestions and clarify lingering questions regarding HPV and the vaccine.  
When asked how to improve the presentation, many helpful suggestions were 
provided. A majority of the participants communicated that more graphic visuals were 
needed to effectively reach adolescents. As one adolescent from Focus Group #4 stated, 
“If you don’t have a visual of what it [HPV infection] looks like, then how are we going 
to know?” Another adolescent from Focus Group #1 expressed a similar sentiment, 
stating, “Yes, we like the pictures, and we would like more graphic ones.” Along the 
same lines, other participants suggested bringing in tangible items that they could interact 
with, such as the needles used to administer the vaccine or the instruments used to 
perform a Pap smear. One adolescent stated “Bring us some of the stuff.  Like bring us 
some of the medicines and tools so that we can actually see what it’s like.  To see how it 
actually looks in real life.”  
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 Another recommended improvement was placing a greater emphasis on the 
seriousness of HPV infection. Many questions were asked during the course of the 
discussions about vaccine side effects, efficacy, dosing schedule, and HPV genotypes, 
topics that were covered by the preceding presentation. For example, an adolescent from 
Focus Group #4 inquired, “There’s different types of HPV?” This suggests that greater 
emphasis, or more time, is needed on these particular topics in future educational 
interventions. 
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Chapter 5: Discussion and Conclusion 
Key Results 
This thesis sought to shed light on the knowledge and attitudes concerning HPV 
and the HPV vaccine, as well as the role of education in shaping knowledge, perceptions, 
and participation in vaccination, in the Hartford, CT adolescent population. The initial 
research model identified three factors hypothesized to influence the intent to be 
vaccinated among adolescents: HPV and HPV vaccine knowledge, physicians’ advice, 
and parental attitudes. Several conclusions can be drawn from the qualitative and 
quantitative data generated in the course of this study.  
Knowledge and Misconceptions 
The majority of adolescents had heard of HPV prior to study participation. 
School, physicians’ offices, the media, and parents were listed as sources of information 
during the focus group discussions. However, there were significant gaps in 
understanding of the nature and consequences of HPV infection, as well as availability of 
the HPV vaccine. For example, prior to the didactic presentation, 33% of participants 
were unaware that HPV is a sexually transmitted disease, while approximately half did 
not know that the HPV vaccine is administered in a 3-dose series. During the focus group 
sessions, when asked what information they learned from the presentation that they did 
not know beforehand, adolescents mentioned a variety of key facts related to infection 
and the vaccine, such as “I didn’t know HPV could cause cancer,” “I didn’t know that 
HPV can have no symptoms,” and “I learned that men can get HPV as well.” Questions 
were also posed that indicated confusion about the modes of transmission, methods of 
prevention, and the prevalence of HPV infections.  
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Certain misconceptions were particularly common, including the view that one 
can acquire HPV with poor hygiene, HPV can cause AIDS, antibiotics can cure HPV, 
and one does not need to use condoms for protection against sexually transmitted 
diseases after HPV vaccination. 
The association of HPV with adolescent sexuality resulted in misapprehensions 
concerning the vaccine. A recurrent theme through both survey and focus group data was 
the idea that only sexually active individuals should receive the HPV vaccine. Prior to the 
presentation, more than one-fifth of participants endorsed this belief, while responses 
during the focus group sessions reinforced the pervasiveness of this idea. A quarter of 
adolescents also endorsed the idea that the HPV vaccine promotes promiscuity in the pre-
presentation survey.   All six physicians interviewed reported cases of parental refusal of 
the vaccine because their children were not sexually active. Physicians also reported 
deflecting parental concerns that vaccinating against HPV may increase sexual activity or 
lower the age of the initiation of sexual activity. 
The literature review demonstrated a dearth of research on male vaccination. The 
media and even the medical community have often referred to HPV vaccine as the 
“Cervical Cancer Vaccine,” downplaying the additional protection afforded for men. This 
gap was reflected in this study by a lack of knowledge among participants concerning 
HPV in men. Prior to the presentation, 58% of adolescents did not believe that HPV can 
lead to cancers of the reproductive system in men, while 13% did not know that both 
males and females can get HPV or that both can receive the vaccine. Close to one-fifth of 
all adolescents surveyed were not aware that men can get HPV from homosexual or 
heterosexual sex before the presentation. During the focus group discussions, adolescents 
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reported that there was a lack of emphasis on male vaccination, from their parents, 
physicians, and the media. This view was supported by the physician interviews, in which 
physicians noted difficulties in recommending the vaccine for boys, citing the female-
oriented advertising of the vaccine, the rarity of sequelae in men, and the association of 
infection with homosexual sex as barriers. Those who were successful in getting male 
patients to accept the vaccine focused discussions with patients on its efficacy against 
penile cancer and genital warts, as well as the benefits for female partners. 
A major goal of this study was to understand how knowledge influences attitudes 
regarding HPV and the HPV vaccine. Prior to the presentation, HPV knowledge and 
belief in the effectiveness of the HPV vaccine was found to be significantly associated.  
Post-presentation, significant associations were found between knowledge and belief in 
both the effectiveness of the vaccine and the seriousness of HPV infection.  These 
associations were supported by discussions during the focus groups, in which adolescents 
felt that many of their peers had not received the vaccine because they were not aware of 
the virus’s consequences, and therefore did not believe the vaccine was important. 
Qualitative data from the physician interviews also reinforced this idea. One physician 
stressed that not knowing that HPV can cause cancer was causing his patients to 
underestimate the importance of the vaccine. These attitudes highlight the need to 
educate parents and adolescents about of the importance of HPV vaccine. 
Barriers and Facilitators of Vaccination 
Several barriers to vaccination were identified. Most had been observed in 
previous studies, but not specifically in the Hartford, Connecticut adolescent population. 
While fear of adverse reactions was postulated to be the major barrier to vaccination 
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intent, quantitative data did not support this hypothesis. Post-presentation, adolescents 
cited believing the vaccine is unsafe (43%) and that the vaccine will cause pain (59%) as 
barriers to vaccination.   
A majority of adolescents cited cost as a barrier, as well as the belief that the 
vaccine is not necessary. Many adolescents noted that the availability of a free vaccine 
would be a motivator in accepting the vaccine, even though the majority of physicians 
agreed that cost was not an issue among their patients. All doctors mentioned that very 
few of their patients were uninsured, likely due to the availability of Husky Health 
insurance in the state of Connecticut. Additionally, the Vaccines for Children (VFC) 
Program covers the cost of the HPV vaccine for the uninsured, making the high cost of 
the vaccine a non-issue among Hartford teens. 
Focus group discussion responses supported the idea that fear of adverse reactions 
was a major reason why many adolescents avoid vaccination. Adolescents responded that 
they were “scared of needles,” stating that the vaccine “probably hurts.” This view was 
echoed in physicians’ responses in which a fear of side effects, reinforced by anti-vaccine 
media coverage, was cited as a major barrier to vaccination among their patients. One 
physician even reported that she herself believed in the reports of neurological side 
effects associated with the vaccine, stating that she could not full endorse it to her 
patients. 
 Much of the controversy related to the initial rollout of the HPV vaccine centered 
on the idea of mandatory vaccination. However, in this study, both adolescents and 
physicians mentioned that the lack of a school entrance mandate made it easier for 
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parents and children to refuse or avoid the vaccine, with two physicians suggesting the 
need for a school mandate to increase vaccination rates in Hartford.  
The three-dose regimen was also blamed numerous times for the low vaccination 
uptake. During the focus group discussions, many adolescents stated that they believed 
their peers were not completing the series because they believed one dose was adequate. 
It was mentioned that a physician reminder to come back for the other two doses would 
be helpful, an idea that physicians also seemed to support. One physician specifically 
recommended that more research be done to determine if one dose of the vaccine would 
be sufficient, or if the vaccine could be given annually, during routine well-child visits, 
with the same efficacy to make administration easier. 
A major goal of this study was to understand the effects of parental attitudes and 
physicians’ advice on vaccination intent. Previous studies have identified the importance 
of provider recommendation and parental support to vaccination initiation.85 This study 
found no significant association between citing parental encouragement to receive the 
vaccine, a lack of parental encouragement, or parental refusal, or citing physician 
recommendation to receive the vaccine, and vaccination intent. Regardless, the surveys 
and focus group discussions did provide some evidence that provider and parental 
attitudes are important for vaccine uptake. Prior to the presentation, 61% of adolescent 
participants cited parental encouragement as a reason to get vaccinated, while 44% cited 
a lack of parental encouragement and parental refusal (33%) as barriers to vaccination. 
During the focus groups, some adolescents mentioned that their parents refused to talk 
about the vaccine, due to its link to sexual activity. Prior to the presentation, 64% of 
adolescents also stated that they believed physician recommendation would encourage a 
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teenager to get vaccinated. Discussions during focus group sessions and physician 
interviews supported the importance of physician advice. Adolescents discussed the fact 
that they would particularly rely on physicians for introduction to the vaccine, series 
completion, and vaccine promotion for males. Most physicians interviewed said that if 
offered the vaccine during a visit, the majority of patients accept. They suggested that 
offering the vaccine as part of routine health maintenance would increase vaccination 
rates. One physician interviewed mentioned concerns that the vaccine has not been 
proven to be effective against cervical cancer or genital warts, and only offers it because 
it is recommended. Additionally, she stated that she does not try to change a patient’s 
mind if the vaccine is refused. This physician reported that only one-third of her patients 
have received the HPV vaccine, providing some evidence that provider attitudes are 
important for vaccine uptake. 
Intent 
Before the presentation, approximately 64% of adolescents responded that they 
intended to receive the HPV vaccine in the next year. Given that prior evidence has 
shown that knowledge and attitudes regarding HPV and its vaccine greatly impact 
vaccination rates, this project aimed to educate participants through a didactic 
presentation. However, there was no statistically significant association found between 
intent to get vaccinated on the post-presentation survey as compared to the pre-
presentation survey, suggesting that the presentation had no effect on intent. Additionally, 
no statistically significant association was found between knowledge and intent, though 
the direction of change was in the direction expected. Belief that HPV infection is serious 
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and belief in the efficacy of the HPV vaccine were also not found to be associated with 
intent.  
Impact of the Educational Intervention 
 A major recurring theme during focus groups and physician interviews was the 
importance of education, particularly the need to better educate adolescents about HPV 
and the availability of the vaccine. A few adolescents mentioned that they were more 
receptive to receiving the vaccine after the presentation, as they understood its 
importance. Additionally, there was a significant increase in mean knowledge from the 
pre-presentation to the post-presentation survey responses, providing evidence that the 
presentation was effective in increasing knowledge. Physicians also expressed their belief 
in the importance of an education program for their patients to increase knowledge of 
HPV and its vaccine, emphasizing that it should ideally target both teens and parents. 
 Areas for improvement were identified through the focus group discussions. 
Questions asked by participants during each discussion session continued to demonstrate 
a wide variety of misconceptions, meaning that many erroneous beliefs remained despite 
the attempted educational intervention. Although topics such as the modes of 
transmission, methods of prevention, and the prevalence of HPV infections were 
addressed in the presentation, adolescents were left with many questions regarding these 
issues. There was particular confusion about the differences between HPV, HSV, and 
HIV. Finally, some adolescents seemed to be unaware of the Pap smear as a preventive 
measure against cervical cancer, suggesting the need for more extensive explanations on 
these topics in future interventions.    
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Generally, adolescents were extremely receptive to the didactic presentation and 
participated enthusiastically in the post-presentation focus group sessions. Suggestions 
for improvement focused on the need for more graphic visuals and items for participants 
to look at, such as the needles used to administer the vaccine or the instruments used to 
perform a Pap smear. Many adolescents wanted a greater emphasis on the seriousness of 
HPV infection as encouragement to get the vaccine. 
Limitations of Current Study 
A major limitation surrounded the narrow scope of adolescents sampled. All of 
the adolescents recruited for this study were involved with community groups focusing 
on service, leadership, and/or education. Thus, the population sampled was a convenience 
sample and not necessarily representative of the overall adolescent population in 
Hartford. Adolescents enrolled in community programs are likely to have greater access 
to health information compared to those who are not. Those less educated or less likely to 
utilize the health care system may not have been included in the sample. This factor could 
affect the generalizability of the results.  
Additionally, due to the exemption status received through the University of 
Connecticut Health Center Institutional Review Board, no identifying or personal 
information were gathered from study participants. Therefore, factors that have been 
shown to affect HPV vaccination rates in other populations, such as race/ethnicity, 
gender, and socioeconomic status, were not accounted for in the implementation of the 
study. Information on current vaccination status was not collected: it may have been the 
case that adolescents who already been immunized had different attitudes and perceptions 
from those who had not had the immunization. The survey question regarding the main 
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outcome measure of vaccination intent assumed that adolescents had not already received 
the vaccine, and therefore was not worded well for those who had already been 
vaccinated at the time of survey administration. Thus, analyses using this measure for this 
population may not have been reliable. Future research should address this issue by 
comparing the opinions of those vaccinated with the unvaccinated. 
Other limitations involved the pre- and post-presentation surveys. All information 
gathered in the survey was self-reported. Health behaviors that are self-reported can be 
biased, which can affect validity. Additionally, knowledge was mostly assessed using 
closed-ended questions. A recent systematic review indicated that HPV knowledge can 
be best measured with open-ended questions as close-ended questions lead to guessing.109 
Future studies should use open-ended questions, to see if similar results are found.  A 
major limitation involved the short follow-up time between the presentation and the post-
presentation survey. The intervention did have a positive effect on knowledge, but it is 
possible that this improvement could have dissipated over time. The post-presentation 
survey was consistently administered within ten to fifteen minutes of the conclusion of 
the presentation. Additionally, no immediate impact was seen with intent, but perhaps 
there was a long-term effect that could not be assessed with the short-term nature of this 
study.  
The final sample involved multiple incomplete surveys, and while there were 75 
pre-presentation surveys collected, only 70 post-presentation surveys were returned. It is 
not understood whether this was because of a lack of interest in the topic, the length of 
the survey, the fact that the survey had to be taken twice, or other demotivating factors. 
Missing answers to all questions counted towards the final knowledge score were counted 
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as incorrect answers, as it could not really be determined if participants did not know the 
answer or just skipped the question. This resulted in low statistical power, and 
statistically significant results related to the outcome measure of vaccination intent were 
not found.   
This project should be viewed as a pilot study, laying the groundwork for a more 
systematic HPV awareness project in Hartford. 
Future Directions and Possible Interventions  
Using a variety of qualitative and quantitative methods, this thesis aimed to 
investigate the knowledge and attitudes of Hartford adolescents concerning HPV and the 
HPV vaccine. This study meant to highlight key areas for intervention that will increase 
knowledge regarding and access to the HPV vaccine, and ultimately, increase vaccination 
rates among Hartford’s youth. Although this study looked into a large number of 
variables related to the main outcome measure of vaccination intent, more work is 
needed. First, this study should be applied to a larger and more diverse population, with 
participants drawn from the entirety of the Hartford community, rather than select 
community groups. Next, the lack of significant findings between the variables tested in 
this thesis and vaccination intent indicate that there is likely a complex range of variables 
that have both direct and indirect relationships with HPV vaccination decisions. Previous 
studies have demonstrated the importance of age, race/ethnicity, gender, socioeconomic 
factors, and education to vaccination uptake, all of which were not accounted for in this 
thesis’ research model. Future studies should incorporate these variables. This study also 
investigated the impact of an educational intervention using unlinked cohort data. It 
would be interesting to evaluate future interventions using linked data, to assess 
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individual change.  Finally, a comparison study of vaccinated versus non-vaccinated 
individuals would be beneficial to further determine the needs of future educational 
interventions. Improved understanding of the reasons for non-vaccination among the 
vaccine-naïve, as well as barriers to vaccine completion among those who have already 
started the series may increase the impact of future educational interventions. 
Potential interventions to increase vaccine uptake among this study’s population 
can be separated into four types, based on the level of implementation: policy, provider, 
family, and individual. Since the HPV vaccine first became available in 2006, an 
increasing number of countries have introduced it into their national programs. It has 
been found that countries with mandatory vaccination and school-based delivery have 
higher vaccine coverage that those with clinic-based, opportunistic programs, such as that 
that currently exists in the United States.56 To date, in the U.S., only the District of 
Columbia, Virginia, and Puerto Rico have mandated vaccination. Connecticut currently 
covers the 3-dose vaccine series under the state’s HUSKY plan for adolescents aged 11 to 
18 years, but no bill concerning a HPV vaccine school mandate has been approved.64 The 
idea of mandatory HPV vaccination has been a controversial one, in part due to its 
assumed link to sexual activity. It is hard to justify these objections from a public health 
standpoint. A school mandate would likely be an effective policy-level intervention to 
increase uptake among Hartford’s youth. Requiring HPV vaccination by law (perhaps 
with an opt-out) would result in more widespread coverage than the current policies that 
rely just on education and encouragement. Qualitative data supported the idea of a 
mandate as a facilitator to vaccination among this study’s population. Adolescents 
mentioned that they would be more likely to receive the vaccine if it was required for 
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school entry, while physicians stated that it was difficult to recommend the vaccine to 
patients without a school mandate. One physician suggested a school-based delivery 
program to improve follow-up and series completion. 
In prior studies, provider recommendation has been found to be one of the 
strongest facilitators of vaccine uptake and conversely, a lack of provider discussion and 
recommendation leads to lower uptake. Qualitative data showed that adolescents seemed 
to particularly rely on physicians for introduction to the vaccine, series completion, and 
vaccine promotion for males. Most physicians interviewed said that if offered the vaccine 
during a visit, the majority of patients accept, emphasizing the need for the vaccine to be 
offered as part of routine health maintenance. According to the CDC, if all missed 
opportunities for vaccination were eliminated, vaccination coverage with at least one 
dose of the HPV vaccine for adolescents would be approximately 93%.73 Therefore, an 
educational intervention targeting providers, perhaps through face-to-face discussions, an 
online program, or through printed educational materials, would likely greatly improve 
vaccination rates in the Hartford area. Further research is needed to assess which method 
would be most effective. Reminder systems or standing orders for nurses or physician 
assistants to vaccinate at routine appointments might also be successful. 
This study attempted to intervene at the individual level, by pilot testing a didactic 
intervention to dispel some of the misconceptions surrounding the HPV vaccination, 
allowing adolescents to have the knowledge to gain control of their health and make 
vaccine-related decisions. The presentation was effective at increasing knowledge, but 
was not significantly associated with vaccination intent. Previous studies, however, have 
demonstrated that knowledge and attitudes regarding HPV and its vaccine do affect 
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vaccination rates. The current study has provided some experiences in developing 
appropriate future educational interventions, targeting both adolescents and their parents 
and guardians. Extensive efforts must be made to educate young men and women about 
the pervasiveness and seriousness of HPV, as well as the advantages of vaccination. 
There is a particular need to focus on the importance of vaccination in males given the 
general lack of knowledge on this topic seen in this study. Ties between the UConn 
Public Health Program, the Hartford Health Department, and the Hartford community 
were forged during this study, laying the groundwork for a future, larger HPV awareness 
project in Hartford. 
As discussed in the introductory chapter, HPV is the most common sexually 
transmitted infection and is an infection with a significant public health impact. The HPV 
vaccine has been proven to be a highly efficacious tool for prevention, but is being 
underutilized, especially among Hartford’s youth and other comparable populations. 
Progress will not be made towards easing the national and statewide HPV-related cancer 
and genital warts burden unless further research is conducted on uptake, attitudes, and 
barriers. Adolescents should be able to make vaccination decisions in a knowledgeable 
manner, with full support from their families, peers, and physicians.   
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Appendix I: Physician Interview Protocol 
 
Hello, we are _____________________, and we are working on a project with the 
Hartford Health Department to increase the rates of HPV vaccination in Hartford youth. 
As a healthcare provider in Hartford, your feedback can give us a valuable perspective of 
healthcare providers regarding HPV vaccination, and barriers to HPV vaccination in our 
target population. You participation is voluntary and your participation will remain 
confidential. To facilitate transcription, your responses will be recorded and then typed 
into a Microsoft Word document. Your name will not be linked to the original recording, 
which will be deleted after transcription and your name will not be connected to the final 
typed notes. This interview should take about 15-20 minutes.  
 
Thank you for your participation.  
 
(Assessing patient panels) We believe that it’s important to understand the demographics 
of the population that you take care of, so that we can gear our interviews based on your 
responses. We understand that exact percentages may be difficult to assess, but rough 
estimates will suffice.  
1. Do you take care of adults, pediatric patients, or both?    
(If both) What percentage of your patients are adults? And what percentage of 
your patients are under the age of 18? 
2.  What percent of your patients are Hartford residents? 
3. What percentage of your patients do not have health insurance?  
4. If you had to estimate, what percentage of your patient panel are white, Black, 
Hispanic, or Asian?   
 
(Assessing physician practice) We also think it’s important to understand your opinions 
of the HPV vaccination in your patients, and barriers to vaccination in your population.  
1. Do you offer the HPV vaccine to your patients?  
(If yes) Do you offer the HPV vaccine as a regular component of your pediatric 
visits?  
(If yes) To what age ranges do you offer the HPV vaccine? And do you offer the 
HPV vaccine to both males and females?  
2. Could you describe how you presented the vaccine to your last patient, and how 
you described it to the adolescent and/or parent? Did they accept or reject the 
vaccination? 
3. What percentage of patients offered the vaccine accept the vaccine? 
4. Do you encounter any difficulties in giving or recommending the HPV vaccine?  
5. Can you give an example of a specific patient or parent that initially refused the 
vaccine and then changed their views when you discussed the reasons for the 
vaccine? What was the reason for refusal? And was it possible for you to change 
their opinion? 
6. What are some other reasons that patients or their parents have refused the 
vaccine?  
7. Is cost a barrier to vaccination in your patients?  
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8. Do you think that your input as a physician can change someone’s mind from 
refusing the vaccine?  
 
(Assessing physician knowledge) The last few questions are regarding your perceptions 
of the HPV vaccine.  
1. Do you think that the HPV vaccine is effective?  
2. Do you have any concerns with giving the vaccine to your patients?  
3. Do you think the HPV vaccine is effective in preventing cervical cancer?  
4. Do you think that the HPV vaccine is effective in preventing genital warts?  
5. If you had to guess, in the United States, what percentage of adolescent females 
have received one shot of the vaccine? And what percentage have received the 
complete three-shot series? 
6. What do you think can be implemented or changed to increase the rates of HPV 
vaccination in Hartford?  
 
 
Thanks for your time. Your responses will be typed into a Microsoft Word document, and 
this information will help us target resources to increase HPV vaccination in Hartford 
youth. 
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Appendix II: Survey Instrument 
 
Unless otherwise specified, please mark one answer per question. It’s important to 
answer each question to the best of your knowledge: 
 
1. Have you ever heard of HPV (Human Papillomavirus)?       
a. Yes      
b. No 
 
2. What do you think HPV is?  
a. A common cold 
b. A skin rash
 
 
c. A sexually transmitted disease 
 
 
d. An infection patients get from hospitals 
e. I don’t know what HPV is 
 
3. What is the most common STD?  (Circle only one) 
a. HPV 
b. Chlamydia 
c. Gonorrhea 
d. Herpes 
e. HIV 
 
4. What can HPV lead to? (Circle all that apply) 
• Cancers of the reproductive system for women (for example, cervical cancer, 
vaginal cancer) 
• Cancers of the reproductive system for men (for example, penile cancer) 
• Mouth/throat cancer 
• AIDS 
• Genital warts 
• Breast cancer 
• None of the above 
 
5. Who does HPV affect? 
a. Female  
b. Male  
c. Both 
 
6. Men can get HPV from homosexual or heterosexual sex.  
a. True 
b. False 
 
7. You would always know if you had an HPV infection. 
a. True  
b. False 
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8. You can get HPV by not keeping yourself clean. 
a. True  
b. False 
 
9. Antibiotics can cure HPV. 
a. True  
b. False 
 
10. If you wait to have sex until after marriage, you cannot get HPV. 
a. True 
b. False 
 
11. HPV is preventable 
a. True 
b. False 
 
12. At what age can HPV vaccination start? (Pick an age) _______ 
 
13. How many doses are there of the HPV vaccine? 
a. 1 
b. 2 
c. 3 
 
14. Who can get the HPV vaccine? 
d. Female  
e. Male  
f. Both 
 
15. The HPV vaccine is only for adults 
a. True  
b. False 
 
16. Only sexually active people should get the vaccine  
a. True  
b. False 
 
17. If you get the HPV vaccine, you don’t need to use condoms because you’re 
protected from sexually transmitted diseases.  
a. True 
b. False 
 
 
18. HPV infection is serious. 
a. True 
b. False 
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19. The HPV vaccine is effective in preventing HPV infection. 
a. True 
b. False 
 
20. The HPV vaccine can prevent cervical cancer. 
a. True 
b. False 
 
21. The HPV vaccine can prevent genital warts. 
a. True 
b. False 
 
22. If a teenage gets the HPV vaccine, he or she will be more likely to have sex. 
a. True 
b. False 
 
23. What are some reasons a teenager would decide to get vaccinated? (Circle all that 
apply) 
• His/her parents told him/her to 
• His/her doctor told him/her to 
• To prevent HPV infection 
• To prevent cervical cancer 
• Because his/her friends all received the vaccine  
• Other (fill in): __________________________________ 
 
24. What are some reasons a teenager would decide NOT to get vaccinated? (Circle 
all that apply) 
• Not knowing where to get the vaccine 
• Thinking the vaccine is not necessary 
• Thinking the vaccine is unsafe 
• Fear that the vaccine will cause pain 
• Cost of the vaccine 
• His/her parents did not tell him/her to 
• His/her parents did not want him/her to 
• Other (fill in): __________________________________ 
 
 
25. Do you plan on being vaccinated in the next year? 
a. Yes 
b. No 
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Appendix III: Focus Group Question Guide 
 
First, the discussion group facilitator will introduce himself or herself and convey the following 
information:   
There are two reasons for conducting the discussion group. First, we want to find out how 
we can improve the presentation we just shared with you. Second, we want to find out 
more about what you think about the HPV vaccine, including what might factors 
influence the decision to get vaccinated.  
You do not need to answer any questions you don't feel comfortable answering and you 
can leave the discussion at any time if you would like. 
There are no right or wrong answers. 
The group is not trying to reach an agreement; you may disagree with others as long as 
you do it in a respectful manner. 
If it is OK with the group, we were hoping to audio recorded the session so that we can 
refer back to it and ensure we did not miss what has been said.  While we will not be 
recording or writing down names, to further protect your privacy, we ask that you do not 
say your name or others names during this discussion.  
During the session, please make sure you speak one at a time, so that when we listen to 
the tape we can understand what people said. 
We ask that you do not repeat outside of this group what the others have said during the 
group discussion. 
Please be honest and free in what you say.  We are here to understand the barriers of 
getting the HPV vaccine and understand that there are many reasons affecting this 
decision. Whatever we talk about here today will not be told to anyone in the community. 
Only the UConn students working on this project will know what was said in the form of 
anonymous information.   
1. How could we improve the presentation?   
2. Is there any content we could add, revise, or remove?  
3. Where have you heard about HPV before today? 
4. What new information did you learn from this presentation that you did not know before? 
5. Do you have any other questions about HPV that we didn't answer in the presentation? 
6. Only 40% of eligible youth have received the HPV vaccine.  Why do you think the 
majority of youth have not been vaccinated? 
7. What do you think would motivate children and adolescents to get vaccinated? 
8. Among girls who receive the first dose, many do not return for the two follow up doses – 
why do you think this is? 
9. As we discussed, vaccination rates are low among boys. Only 20% of boys receive the 1st 
dose, and only 7% of boys receive all 3 doses.  
a. Why do you think the vaccination rate is so low for boys? 
b. Why do you think it is higher among girls compared to boys? 
